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Abstract: Glucose monitoring devices (e.g., glucometer) are widely established as a 
successful diabetes management and point-of-care testing systems. However, non-
glucose markers such as hormones, autoantibodies, proteins, and other small molecules 
can provide better assessments for the prediction and management of the disorder and 
identification of diabetes classes (e.g., type 1 and type 2). The challenges our research 
community faces in designing an analytical device for such markers are the dynamic 
range, limit of detection, selective isolation of the analyte, higher background noise due 
to clinical matrix, and ability to transform the system into a cheap point-of-care device. 
The main research objective is to design and develop a new diabetes sensor surface 
chemistry to advance the current analytical capabilities of detecting serum insulin and 
autoantibodies through novel surface designs.  
 
In this dissertation, I discuss the development of covalent and noncovalent carboxylations 
of carbon nanotubes for sensitivity enhancement of clinical immunosensors for insulin 
detection. Additionally, the validation of an electrochemical immunosensor for detection 
of serum glutamic acid decarboxylase-65 autoantibody through surface plasmon 
resonance imaging and establishing binding parameters for the antigen-antibody binding 
are reported. Finally, a low-cost paper-based label-free electrochemical approach is 
presented for sensitive detection of serum insulin. The dissertation critically discusses the 
quantitative analytical details of the developed sensors’ surfaces.   
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CHAPTER I 
 
 
IMMUNOSENSOR DESIGNS TO ENABLE CLINICALLY REQUIRED PICOMOLAR 
DETECTION OF SERUM INSULIN AND AUTOANTIBODIES 
 
1.1 Diabetes pandemic 
The growing diabetic disorders and their complications (retinopathy, nephropathy, neuropathy, 
cardiovascular diseases, and others) are significant health problems and a great economic burden 
in the United States and globally.1  “Global report on diabetes” from World Health Organization 
(WHO) indicated that 422 million adults have diabetes.2 In the United States, 30.3 million people 
have diabetes which translates to about 1 in every 10 persons, and accounts for approximately 
$245 billion on national healthcare costs.3  
The American Diabetes Association has recently reclassified diabetes into four types: 
type 1 diabetes (T1D), type 2 diabetes (T2D), gestational diabetes mellitus (GDM), and specific 
types of diabetes due to other causes such as, diseased pancreas and chemically induced diabetes 
(Table 1.1).4 Additionally, there is one more broadly accepted category of diabetes known as 
latent autoimmune diabetes in adults (LADA).  LADA is characterized by slow progression of β-
cell failure and presence of autoantibodies against β-cell antigens, however the patient may not 
require the administration of external insulin for upwards of 6 months after diagnosis.5 
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Table 1.1. Generally accepted classification of diabetes. 
 
 
 
 
 
 
One of the major achievements in the fight against diabetes was the discovery of insulin 
in pancreatic extracts of dogs. In 1922, Frederick Banting and Charles Best, with help and 
guidance from John Macleod discovered insulin and its significance in glucose metabolism and 
homeostasis.6 Another major accomplishment in the fight against diabetes was the design and 
development of the blood glucose sensor. 
1.2 State of the insulin sensors and early diabetes markers 
1.2.1 Blood glucose sensor 
In 1962, Leland C. Clark and Champ Lyons first demonstrated a sensor for measuring glucose 
concentrations that used glucose oxidase (GOx), an enzyme that converts glucose into gluconic 
acid, and measured oxygen concentration that was proportional to glucose concentration.7 Since 
then, a variety of sensors able to measure glucose concentrations has been demonstrated and 
perfected such that there is currently a large range of such glucometers in commercial settings. 
These glucose sensors have been mainly divided into three generations depending on how they 
communicate with the electrode and generate signals. Almost all of the glucose sensors depend 
on GOx for enzymatic conversion of glucose into gluconic acid. The first generation of the 
Type of diabetes Characteristic features 
Type 1 diabetes (T1D) Autoimmune β-cell destruction, insulin 
deficiency 
Type 2 diabetes (T2D) Progressive loss of insulin secretion, insulin 
resistance 
Gestational diabetes mellitus 
(GDM) 
Developed during pregnancy 
Specific type of diabetes Monogenic diabetes syndrome; diseased 
exocrine pancreas induced; drug/chemical 
induced 
Latent autoimmune diabetes in 
adults (LADA) 
Slow progression of β-cell failure, presence of 
autoantibodies, does not require insulin 
administration initially 
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glucose sensors used O2 as the mediator, the second generation incorporated the use of artificial 
mediators to avoid O2 deficit conditions, and the third generation worked without employing any 
mediators.8,9  
  While glucometers are well established as a Point-of-Care (POC) benchmark, the debate 
about the technical accuracy versus the clinical accuracy of these devices continues.10 Moreover, 
glucometers do not provide information relating to difference in the type of diabetes or a person’s 
tendency to develop a clinical onset.  
1.2.2 Insulin sensors 
Insulin is a 5.8 kDa polypeptide hormone responsible for the glucose homeostasis. It consists of 
two peptide chains known as A-chain and B-chain linked together with two disulfide bonds, and 
an additional disulfide bond within A-chain (Figure 1.1). The A-chain consists of 21 amino acids 
while B-chain has 30 amino acids. Insulin is secreted by the β-cells in the Islets of Langerhans as 
preproinsulin which consists of the two peptide chains, a C-peptide region, and an additional 24-
residue signal peptide.11 This precursor cleaves off to become proinsulin which again cleaves off 
into insulin and C-peptide.  
 
 
 
 
 
Figure 1.1. Structure of human insulin [PDB ID: 4F1A]. 
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Detecting insulin in biological fluids can provide critical information that can help in the 
course of diabetes treatment. However, unlike millimolar glucose, insulin is present at very low 
concentrations (picomolar) in human blood. In clinical settings, fasting blood sugar level less than 
100 mg dL-1 (< 5.6 mM) is normal, 100-125 mg dL-1 (5.6 – 6.9 mM) is considered prediabetes, 
and 126 mg dL-1 or higher (> 7 mM) indicates diabetes.12 The fasting blood insulin concentrations 
under normal conditions is ~ 50 pM, and < 50 pM and > 70 pM indicates onsets of type 1 and 
type 2 diabetes respectively.13- 16 Due to this ultra-low concentration, designing analytical sensor 
that is sensitive, selective, robust, and reproducible for such non-glucose biomarkers is 
challenging.  
Previous research from our laboratory demonstrated unique surface design strategies for 
measuring insulin in biofluids. Our group reported the first electrochemical mass sensor that 
detected serum insulin conjugated to magnetic particles and captured via antibodies immobilized 
on thiol modified gold coated quartz resonators.17 The magnetic particles-insulin conjugation 
chemistry was later extended to design a voltammetric sensor on a pyrolytic graphite electrode 
modified with multiwall carbon nanotubes and 1-pyrenebutyric acid assembly.18 The carbon 
nanostructure immunoassembly allowed a detection limit of 5 pM of insulin in 50% human 
serum. Additionally, the serum matrix effect on the detection signal was studied on a surface 
plasmon resonance imager (SPRi) platform by monitoring serum insulin dilution captured by 
magnetic nanoparticles.19 Two times diluted serum insulin conjugated to magnetic particles 
exhibited higher SPRi signals achieving detection limit of 5 pM, when compared to other serum 
dilutions. In another work, SPRi was used to detect two biomarkers in one chip, insulin and 
glycated hemoglobin (HbA1c), in 20-times diluted whole blood.20 Magnetite nanoparticles 
decorated with quantum dots were used for covalent immobilization of aptamers for selective 
isolation and capturing of insulin and HbA1c in the diluted whole blood samples. The detection 
limits for insulin and HbA1c were 4 pM and 1% respectively. 
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Recently, Li et al. demonstrated an Orange II (water soluble electroactive dye) and Au 
nanoparticles composites on a graphene modified glassy carbon electrode to measure insulin 
concentration using differential pulse voltammetry.21 The method allowed to achieve an 
impressive linear range of 10 fM – 500 pM with a detection limit of 6 fM. 
Yagati et al. demonstrated a reduced graphene oxide modified interdigitated chain 
electrode for label free detection of insulin concentrations prepared in buffer solution.22 A change 
in the relative capacitance was monitored as the detection signal for increasing insulin 
concentrations. Another report by Tabrizi et al. employed differential pulse voltammetry to detect 
insulin molecules on screen printed electrodes modified with ordered mesoporous carbon that was 
chemically modified with 1,3,4,8-pyrenetetrasulfonate to immobilize insulin aptamers.23 Using 
methylene blue as the redox probe, a linear range of 1.0 fM – 10.0 pM and detection limit of 0.18 
fM was achieved. 
This dissertation explores strategies for enhancing immunosensing techniques applicable 
to diabetes biomarkers using covalent and noncovalent carboxylations of carbon nanotubes, and 
plasmonic property of graphene. Additionally, a low-cost electrochemical approach for sensitive 
detection of serum insulin molecules is reported.  
1.2.3 Autoantibodies in T1D 
T1D is an autoimmune disease categorized by the destruction of pancreatic β-cells that has been 
related to genetic, environmental, and metabolic factors. The destruction of β-cells leads to 
insufficient production of insulin that eventually results in hyperglycemia. Studies have reported 
that autoimmunity occurs years earlier than the clinical onset of T1D. This phase is also 
characterized by the presence of autoantibodies against β-cell antigens namely: glutamic acid 
decarboxylase 65 (GAD65), tyrosine phosphatase-related islet antigen 2 (IA-2), insulin, 
transglutaminase, and zinc transporter-8.24 Nearly all T1D patients have at least one of these 
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autoantibodies. Additionally, adults testing positive for two or more autoantibodies have ~77% 
chance of developing T1D in the next five years. As per a study, 43.5% of children who tested 
positive for two or more autoantibodies developed T1D within 5 years, 69.7% of them within 10 
years, and 84.2% within 15 years.25 These statistics highlight the importance of detecting the 
aforementioned biomarkers in clinical matrices.  
In 1995, Falorni et al. reported a radioimmunoassay for detection of GAD-65 
autoantibodies using 35S or 3H recombinant human ligands.26 Few years later, Walikonis et al. 
reported a radioimmunoassay for the detection of the same biomolecule using 125I as labels.27 
Zhang et al. reported a plasmonic chip for detecting autoantibodies for T1D using IRDye800-
labeled anti-human IgG antibodies and studying fluorescence spectroscopy.28 While their assay 
time was less than 2 hours, the multiple surface modifications took more than 12 hours and 
required a microarray printing robot and incorporation of expensive fluorescence labels. In 
addition, the study required complicated data manipulations. Zhao et al. developed an 
electrochemiluminescence assay for multiplexed detection of four autoantibodies.29 However, 
their double antigen assay required multiple labels including sulfo- and linker-tagged antigens 
with overall incubations time surpassing 24 hours. 3-Screen islet cell autoantibody enzyme-linked 
immunosorbent assay (ELISA) reported by Amoroso et al. also employed double antigen 
technique with multiple labels and incubation time surpassing 24 hours.30  
1.3 Limitations and need for new sensors with simplicity and sensitivity for real samples 
While there have been unique sensor designs exhibited for diabetic biomarkers, they all lack in 
area of simplicity by requiring complicated surface designs. Additionally, most of the 
aforementioned sensors detect biomarkers in buffer solution. This results in uncertain outcomes 
when the sensing technique is translated to biological samples. Increase in background signal, 
decrease in dynamic range, and higher limit of detections are some of the limitations encountered 
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when biological samples are involved. Moreover, the assay time tends to require long hours as 
well as high-end instruments with expensive labels. Additionally, translating the biosensor into a 
point-of-care testing (POCT) system, which is encouraged by NIH, also becomes tricky. 
1.4 Significance of electrochemical sensors 
Electrochemical methods are the basis of modern biosensing techniques as they provide a 
relatively cheaper alternative to expensive laboratory instruments in a clinical setting. 
Electrochemical biosensors provide the platform for converting a biological event into an 
electronic signal thus allowing the analysis of the biological environment. A typical 
electrochemical cell is composed of a working electrode (WE), reference electrode (RE), and 
counter electrode (CE). 
Detection of biomarkers can be performed via several techniques including, but not 
limited to, radioimmunoassay, enzyme-linked immunosorbent assay (ELISA), liquid 
chromatography, electrochemical, and optical methods. Among these, electrochemical methods 
are widely popular as they do not require radioactive labels or sophisticated instruments, but a 
benchtop potentiostat only. Furthermore, an electrochemical sensor can potentially be transferred 
into a POCT system. 
1.4.1 Amperometry 
Amperometry is an electrochemical method that continuously measures current resulting from the 
redox process of an electroactive species at the WE at an applied constant potential (Figure 1.2). 
The current is proportional to the bulk concentration of the electroactive species in the sample. 
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Figure 1.2. Constant potential waveform for amperometric techniques. 
 Using flow-injection amperometry, we designed an immunosensor for insulin detection 
in 20-fold diluted human serum (Figure 1.3). π-π stacking of 1-pyenebutyric acid over dry-coated 
carboxylated multiwall carbon nanotubes increased the number of biomolecule immobilization 
sites thereby, increasing the number of immobilized capture molecules for insulin detection. The 
current signals were proportional to the amount of insulin bound to the sensor surface (Figure 1.3-
B). 
Figure 1.3. (A) Amperometric immunosensor for insulin detection 20-fold diluted in human 
serum. (B) Current signals corresponding to different of insulin concentrations bound to the 
sensor surface with a representative patient sample analysis. Reproduced from Niroula, J.; 
Premaratne, G.; Ali Shojaee, S.; Lucca, D. A.; Krishnan, S. Chem. Commun. 2016, 52, 13039-
13042 with permission from the Royal Society of Chemistry. 
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1.4.2 Electrochemical impedance spectroscopy (EIS) 
Electrochemical impedance is the measure of the ability of a circuit to resist the flow of electric 
current and is usually measured by applying an AC potential to an electrochemical cell and 
measuring the current. Generally, a sinusoidal potential excitation is applied which results in an 
AC current signal. This current signal will be sinusoidal at the same frequency but is shifted in 
phase (ϕ). If an excitation signal, Et, results in the response signal, It, the electrochemical 
impedance (Z) is expressed as shown below. 
𝑍𝑍 =  𝐸𝐸𝑡𝑡
𝐼𝐼𝑡𝑡
=  𝐸𝐸0 sin(𝜔𝜔𝜔𝜔)
𝐼𝐼0 sin(𝜔𝜔𝜔𝜔+𝜙𝜙) =  𝑍𝑍0 sin(𝜔𝜔𝜔𝜔)sin(𝜔𝜔𝜔𝜔+𝜙𝜙)  (Equation 1.1) 
Here, Et is potential at time t, E0 is amplitude of the signal, ω is the radial frequency, It is response 
signal, I0 amplitude of signal, and Z0 is the impedance magnitude. EIS can also be represented as 
a complex number, Z = Zre + jZim, where Zre denotes real impedance and Zim denotes imaginary 
impedance. 
 
 
 
 
 
 
 
Figure 1.4. Bode plot representing capacitance and resistance region of a sensor. 
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In the presence of a redox probe, a faradaic process occurs where resistance of the 
electrolyte solution, Rs, Warburg impedance, ZW, double layer capacitance, Cdl, and electron 
transfer resistance, Ret, all contribute to the interfacial electronic circuit. However, in the case of a 
label-free approach, only non-faradaic impedance comes into play. Here, the ZW and Ret tends to 
infinity and only the Cdl, which depends on the dielectric permittivity of the surface molecules 
becomes the variable unit.31 This non-faradaic behavior is demonstrated by the Bode plot (Figure 
1.4). At higher frequencies, the sensor behaves more as a resistor and the impedance remains 
constant. However, while scanning at lower frequencies, where the phase angle is closer to -90°, 
the sensor behaves significantly as a capacitor.32 Unlike faradaic processes and ELISA, non-
faradaic EIS is label-free technique. 
Using this concept, we designed a paper-based strategy to detect insulin molecules spiked 
in 10% human serum (Figure 1.5). The Cdl becomes the Cinterface representing the interfacial 
capacitance. While resistance dominates at higher frequencies, the sensor behaves as capacitor at 
lower frequencies. The relative change in capacitance was monitored at 10 Hz frequency for 
increasing concentrations of serum insulin. In this study, carboxylated graphene was chosen for 
its aqueous dispersibility and superior biocompatibility. Additionally, the designed sensor was 
validated using amperometric technique. 
 
Figure 1.5. Design of the 
paper-based capacitive 
sensor for monitoring 
insulin concentrations in 
10% human serum.  
                                       
11 
 
1.5 Independent validation with surface plasmon resonance imaging (SPRi) 
In another study, we used SPRi as a validation method of an electrochemical detection technique 
based on faradaic-EIS for glutamic acid decarboxylase-65 (GAD-65) autoantibodies detection in 
human serum. Carboxylated graphene was used to immobilize GAD-65 antigen as the 
biorecognition element, which captured autoantibodies from serum samples. This study allowed 
to establish optimal conditions and obtain binding parameters for the GAD-65 antigen-antibody 
interactions. 
  Surface plasmon resonance (SPR) is a label-free optical detection method that has gained 
significance in the analysis of biomolecular interactions. SPR refers to the collective oscillations 
of the conduction electrons in noble metals (usually thin films of gold). Surface plasmons (SPs) 
are electromagnetic waves that are excited by p-polarized light and propagate parallel to the 
surface while decaying exponentially away from the surface. The maximum decay length of a SP 
is ~ 200 nm, and SPR is used to monitor changes in the index of refraction caused by changes in 
thickness of the molecular layer above the gold surface within this length.33 SPR allows real-time 
monitoring of biomolecular interactions as well as provides binding kinetics and affinity 
information regarding the same.34 
In SPRi, both the incident angle and wavelength are fixed while a CCD camera monitors 
the reflected light in an array format (GWC Technologies, Inc). Initially, the SPR angle is 
adjusted and then the biomolecular interactions are monitored upon changes in the intensity of 
reflected light in an array format (Figure 1.6). The SPR angle is the angle of incidence where the 
reflected intensity is at minimum due to maximum generation of SPs. The array format allows 
multiple measurement of biomolecular interactions at the same time.   
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Figure 1.6.  (A) Measurement of reflectivity as a function of incident angle. Initially, an SPR 
angle is determined (red curve) and after molecules adsorb to the surface the angle shifts to higher 
angle (blue curve.) SPRi monitors change in reflectivity (Δ%R) based at a fixed angle (dashed-
black-line). (B) The SPRi intensity of reflectivity increases with increasing biomolecular 
interactions at the gold surface.  
1.6 Rationale and novelty of approaches derived in this dissertation research 
The sensitivity of an immunosensor mostly depends on analyte loading which in turn depends on 
availability of biorecognition sites. In Chapter II, we demonstrate a novel approach for increasing 
the number of immobilization sites for biorecognition elements (insulin antibodies in this case) by 
π-π stacking 1-pyrenebutyric acid on basal sidewalls of carboxylated multiwall carbon nanotubes. 
The strategy of combining covalent and non-covalent carboxylations of carbon nanotubes 
increases the number of carboxyl groups on sensor surface by approximately 4.5 times when 
compared to carboxylated nanotubes only. This in turn allowed ~ 3 times more antibody 
immobilization on the sensor surface. 
 Chapter III presents a SPR immunoarray validation for GAD-65 antigen-antibody 
interaction. Graphene as a novel 2D nanostructure is utilized to enhance the SPRi signals for 
antigen antibody interactions. Raman spectroscopy demonstrated that graphene on gold 
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composites enhances plasmonic properties by ~ 5.5 times. Additionally, binding parameters for 
the antigen-antibody interactions were also established. 
 Finally, Chapter IV reports the first paper-based label-free detection of serum insulin. 
This study provides the initial assessment to shift towards label-free detection of biomolecules in 
biological matrices. The designed paper-based detection facilitates a low-cost methods of analyte 
detection.  
1.7 Significance of results obtained 
The results obtained in this dissertation enabled the detection of picomolar concentrations of 
serum insulin without using complicated surface designs. In principle, the designed sensor 
surfaces can be adapted to detect any biomolecule or small molecule of interest. We also report a 
paper-based method for label-free detection of serum insulin using non-faradaic EIS. This has 
allowed us to focus towards multiplexing on paper-based surface for other diabetes markers. 
ELISA correlations using patient samples demonstrated the applicability of the designed sensors 
in clinical setting.  
Using SPR immunoarray, we validated the electrochemical array for detection of GAD-
65 autoantibody as well as presented the binding constant for the antigen-antibody interactions. 
The binding parameters can be used as a standard reference for monitoring GAD-65 antigen-
antibody interaction in other detection approaches. Additionally, the inclusion of graphene 
exhibited a plasmon enhancing property as well as lowered background signals. 
 These studies do have clear limitations. For example, achieving a wider dynamic range 
with lower limits of detection in undiluted biological matrices would have been ideal. 
Nevertheless, the dissertation demonstrates novel sensor surface designs with quantitative details 
on the surface carboxyl groups and protein loading which surpasses traditional limitations. 
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1.8 Summary 
The ultrasensitive detection of diabetes biomarkers can enable an optimized management of the 
disorder and potentially provide a prediction model for the onset of the disease. This dissertation 
demonstrates the surface chemistry for sensitive detection of serum insulin in clinically relevant 
range. Additionally, a validation of SPR immunoarray is presented for detection of autoantibodies 
in serum matrix. The surface chemistry developed is useful for detection of any other 
biomolecules using relevant antigen-antibody complexes. The future direction encompasses 
multiplexing diabetes biomarkers in a paper-based platform in undiluted biological matrix for 
point-of-care testing. 
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CHAPTER II 
 
 
COVALENT AND NONCOVALENT CARBOXYLATIONS OF CARBON NANOTUBES 
FOR SENSITIVITY ENHANCEMENT OF CLINICAL IMMNUOSENSORS 
 
2.1 Introduction 
The large conductive surface area of carbon nanotubes along with ease of functionalization has 
allowed the development of highly sensitive electrochemical immunosensors and electrodes 
featuring chemical or enzymatic catalysts yielding high electrocatalytic currents.35- 42 
Conventional covalent carboxylation (e.g., by acid treatment, amidation, thiolation) and recently 
developed noncovalent carboxylation of carbon nanotubes (e.g., π-π interactions, DNA wrapping) 
have a remarkable significance in the multiple areas of electronics, biosensors, engineering, 
materials science, fuel cells, and renewable energy.43- 49 Additionally, new functionalization 
strategies of carbon nanotubes to obtain a fundamental understanding of its structure in enzyme 
biosensors and electrocatalysis are still evolving.50- 52 
This study describes the π-π stacking of 1-pyrenebutyric acid (Py-COOH) with 
carboxylated multiwall carbon nanotubes (MWNT-COOH) on gold screen printed electrodes 
(AuSPEs) for covalent immobilization of monoclonal insulin antibody (Absurface) and detection of 
insulin spiked in 5% serum. To minimize the serum matrix effect and amplify the current signal,  
Adapted from Niroula, J.; Premaratne, G.; Ali Shojaee, S.; Lucca, D. A.; Krishnan, S. Chem. Commun. 2016, 52, 13039-13042 with 
permission from the Royal Society of Chemistry. 
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we captured insulin present in serum by horseradish peroxidase (HPR)-labeled second insulin 
antibody (detection antibody) attached to magnetite (Fe3O4, 1 mg contains ~ 1.8 x 1012 particles) 
nanoparticles. Using nanoparticles labeled with insulin antibodies allows easy isolation of insulin 
molecules from serum matrix. This study reports the effect of combining covalent and 
noncovalent carboxylations of MWNTs for developing highly sensitive serum insulin 
amperometric immunosensors.  The application of this methodology to other enzyme-catalyzed 
reactions seeking sensing and electrocatalysis adds an immense significance to the findings in this 
report. 
 
 
 
 
 
 
 
 
Figure 2.1. Schematic representation of the designed serum insulin immunosensor. 
Figure 2.1 shows the amperometric insulin immunosensor designed in this study for 
measuring insulin levels in human serum. The detailed experimental procedure for construction 
of the immunosensor under optimized conditions is provided in the experimental section. In brief, 
an AuSPE was dry coated with MWNT-COOH. Py-COOH was then π-π stacked onto the basal 
plane sidewalls of the MWNT-COOH surface.35,53,54 Following this, the surface carboxyl groups 
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were activated by treating with a freshly prepared solution of 1-ethyl-3-(3-
(dimethylamino)propyl)-carbodiimide (EDC, 0.4 M) and N-hydroxysuccinimide (NHS, 0.1 M) 
mixture in deionized water to convert them into N-succinimidyl esters for covalent attachment 
with the lysine residues of Absurface (amine-carboxylic acid coupling chemistry to form amide 
bonds).54 The surface was then blocked with bovine serum albumin (2% BSA) to minimize 
nonspecific binding.55 The sensor was incubated with serum insulin conjugates prepared by 
capturing insulin from serum using poly(acrylic acid)-functionalized magnetite nanoparticles 
(MNPs) that are covalently attached with HRP-labeled rabbit polyclonal anti-insulin antibody 
(AbHRP). The resulting serum insulin conjugate is denoted as MNP-AbHRP-insulin (Figure 2.1). 
Amperometric signals were monitored for the binding of MNP-AbHRP-insulin conjugates 
onto Absurface at an applied constant potential of – 0.1 V vs. a pseudo Ag reference electrode. All 
procedures were completed off-line except the detection step. For detection, a solution containing 
1 mM hydroquinone (HQ) mediator and 0.5 mM H2O2 in phosphate buffered saline (PBS, 
10mM), pH 7.4 was delivered onto the sensor surface via a syringe pump at a flow rate of 200 µL 
min-1. The HRP-label (present in the MNP-AbHRP-insulin conjugate) catalyzed oxidation of HQ to 
benzoquinone in the presence of H2O2 was monitored as current signals, which are proportional to 
the concentration of serum insulin bound on the AuSPE sensor surface (Figure 2.1). The MNP-
AbHRP strategy offers the isolation of insulin from complex serum by simple use of a small 
magnet, improved antibody-antigen binding selectivity, increased signals from large antibody-
insulin complexes carrying MNPs and minimized interferences of signals from the free serum 
matrix.17,56 
Figure 2.2 shows the experimental setup of the immunosensor for serum insulin 
detection. Once the immunosensor electrode was connected to a 3-electrode configuration in a 
microfluidic channel, a constant –0.1 V potential was applied. A syringe pump was used to 
deliver 1 mM HQ and 0.5 mM H2O2 containing PBS solution over the serum insulin-bound 
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sensor surface. Corresponding amperometric signals were recorded by a computer connected with 
a potentiostat. 
 
 
 
 
 
 
Figure 2.2. Experimental setup of the designed immunosensor. The top view of the microfluidic 
channel is shown on the bottom-left corner.  
2.2 Experimental 
2.2.1 Reagents and materials 
Screen-printed gold electrodes (AuSPEs, DRP-C220BT, 0.126 cm2 Au geometric area, DropSens 
Inc.) were obtained from Metrohm USA, Inc. (Riverview, FL). Carboxylic acid-functionalized 
multiwalled carbon nanotubes (MWNT-COOH), 1-ethyl-3-(3-(dimethylamino)propyl)- 
carbodiimide (EDC), N-hydroxysuccinimide (NHS), mouse monoclonal anti-insulin antibody 
(Absurface), bovine serum albumin (BSA, ≥ 98% purity), hydrogen peroxide solution (H2O2), and 
hydroquinone (HQ) were purchased from Sigma-Aldrich (St. Louis, MO). 1-Pyrenebutyric acid 
(Py-COOH) and the NanoOrange Protein Quantitation Kit were purchased from Thermo Fisher 
Scientific (Waltham, MA). Recombinant human insulin (> 99%) from yeast was purchased from 
Kerafast, Inc. (Boston, MA). Horseradish peroxidase (HRP)-labeled rabbit polyclonal anti-insulin 
antibody (AbHRP) was purchased from LifeSpan BioSciences, Inc. (Seattle, WA). Poly(acrylic 
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acid)-functionalized magnetic nanoparticles (MNPs, fluidMAG-PAS, 100 nm hydrodynamic 
diameter, 1 mg contains ~1.8 x 1012 number of particles) was obtained from Chemicell GmbH 
(Berlin, Germany). A T2D patient serum sample was sourced from BioreclamationIVT 
(Westbury, NY). Thionyl chloride was purchased from TCI America (Portland, OR). 4-
nitrophenol (97%), 1,4-dioxane (99+%), and trimethylamine (99%) were obtained from Alfa 
Aesar (Ward Hill, MA). 
2.2.2 Apparatus and instrumentation  
The surface morphology of the insulin immunosensor was imaged using scanning electron 
microscopy (SEM, Model: JEOL JXM 6400). To characterize the stepwise surface modification 
of the immunosensor on the electrode, a Nicolet iS50 Fourier transform infrared spectrometer 
(FTIR, Thermo Scientific) and a WITec alpha-300 confocal Raman microscope (WITec GmbH, 
Ulm, Germany) were used. Amperometric responses were recorded using a CHI 6017E 
electrochemical analyzer (CH Instruments, Austin, TX). All electrochemical studies were 
conducted in phosphate buffered saline (PBS, pH 7.4, 10 mM phosphate, 0.14 M NaCl, 2.7 mM 
KCl) at room temperature (23 oC). Cyclic voltammetric quantitation of surface -COOH groups 
was performed with a CHI 6017E electrochemical workstation in phosphate buffer (pH 6.8). 
Fluorescence measurements for Absurface quantitation was carried out using a Cary Eclipse 
Fluorescence Spectrophotometer (Agilent Technologies, Santa Clara, CA).  
2.2.3 Preparation of the insulin detection antibody-magnetic nanoparticles conjugate (MNP-
AbHRP-insulin) 
The conjugates were prepared using the protocol provided by the manufacturer (Chemicell 
GmbH). Briefly, 150 µL of a freshly prepared aqueous solution of 0.4 M EDC and 0.1 M NHS 
was added to 68 µL of MNPs (25 mg/mL, i.e., 1.7 mg) and gently rotated for 10 minutes to 
activate the poly(acrylic acid) –COOH groups of MNPs. The activated MNPs were separated 
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using a small cleaved magnet (this provides better surface roughness than a smooth magnetic 
surface) within 15 s and the supernatant consisting of the unreacted EDC/NHS solution was 
removed. The MNPs were washed twice with 150 µL of PBS. Then, 20 µL of HRP labeled anti-
insulin antibody (0.42 mg/mL) in 250 µL of PBS buffer was added to the activated MNPs and the 
mixture was rotated gently for 1 hour at room temperature. The obtained MNP-AbHRP was 
washed three times with 0.1% BSA in PBS (PBS-BSA). The washed MNP-AbHRP was divided 
equally into six aliquots. To each aliquot, 140 µL of different insulin concentrations spiked in 5% 
human serum was added and gently rotated for 1 hour. Thus obtained, MNP-AbHRP-insulin 
conjugates were washed three times with PBS-BSA. The conjugates were then suspended in 140 
µL PBS giving a final concentration of 2 mg/mL MNPs in the prepared conjugates, an optimal 
concentration that provided good reproducibility in the sensor. Similar protocol was used to 
prepare bioconjugates for a T2D patient’s serum sample by diluting it 20-times in PBS to obtain 
5% serum containing insulin. 
2.2.4 Preparation of immunosensor electrodes 
AuSPEs were cleaned by washing them in ethanol and then with water. A 3.5 µL suspension of 
MWNT-COOH (2 mg/mL) in dimethylformamide (DMF) was added to each AuSPE surface and 
dried at room temperature. Then 7 µL of 1-pyrenebutyric acid (Py-COOH, 10 mM) in DMF was 
added to each AuSPE and incubated for 1 hour in a closed moisturized environment to avoid 
drying of the Py-COOH solution. This allowed the formation of strong π-π stacked MWNT-
COOH/Py-COOH complexes on the AuSPEs. The electrodes were rinsed well with water. All 
further modifications on the electrodes were done at 4 ˚C. To the MWNT-COOH/Py-COOH 
modified electrodes, 10 µL of an aqueous solution containing the mixture of 0.4 M EDC and 0.1 
M NHS was added (per electrode) to activate the surface carboxylic acid groups for a duration of 
10 min. The electrodes were rinsed with PBS and a 10 µL solution of 100 µg/mL monoclonal 
anti-insulin antibody (Absurface) in PBS was added to each electrode and incubated for 1 hour. This 
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allowed for the amine-carboxylic acid coupling reaction and formation of the covalently attached 
Absurface via amide bonds onto the MWNT-COOH/Py-COOH modified AuSPEs. The electrodes 
were then rinsed with PBS, and the surface was blocked for minimizing nonspecific binding by 
adding 10 µL of 2% BSA in PBS and incubating for 30 minutes. The electrodes were then rinsed 
with PBS again. Finally, 10 µL of MNP-AbHRP-insulin conjugates prepared with various serum 
insulin concentrations were placed on the electrodes and incubated for 1 hour. The electrodes 
were rinsed in PBS and were fitted into a microfluidic channel to measure amperometric 
responses at an applied constant potential of -0.1 V vs pseudo Ag while delivering PBS 
containing 1 mM HQ and 0.5 mM H2O2 over the immunosensor surface at a flow rate of 200 µL 
min-1. Similar to the described MWNT-COOH/Py-COOH/Absurface/ BSA immunosensor, we 
designed a sensor without the π-π stacking of Py-COOH (i.e., MWNT-COOH/ Absurface/BSA on 
AuSPEs) for serum insulin measurements using the MNP-AbHRP-insulin conjugation strategy for 
comparative measurements. 
2.3 Results and discussion 
2.3.1 Immunosensor optimization and characterization 
The scanning electron microscopy (SEM) image of bare AuSPEs (Figure 2.3-A) shows the 
characteristic roughness that would be expected for the purchased rough gold surface SPEs 
manufactured by curing gold ink over a ceramic substrate at low temperature (DropSens Inc.). 
Dry-coating MWNT-COOH onto AuSPEs resulted in cylindrical tubular structures of the 
nanotubes (Figure 2.3-B). Further modifications of the electrode with π-π stacked Py-COOH, 
covalently attached Absurface, and BSA blocking respectively changed the tubular structures to 
become thicker and denser (Figures 2.3-C, D, and E). After the selective binding of the MNP-
AbHRP-insulin conjugate onto Absurface, the presence of the nanoparticles bound on the sensor 
surface was observed (Figure 2.3-F). 
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Figure 2.3. SEM images of A. bare AuSPE, B. AuSPE/MWNT-COOH, C. AuSPE/MWNT-
COOH/Py-COOH, D. AuSPE/MWNT-COOH/Py-COOH/Absurface, E. AuSPE/MWNT-
COOH/Py-COOH/ Absurface/BSA, and F. AuSPE/MWNT-COOH/Py-COOH/Absurface /BSA/MNP-
AbHRP-insulin (the presence of surface bound nanoparticle conjugates can be seen in the image). 
Figure 2.4 shows the stepwise Fourier transform infrared spectroscopy characterization of 
the designed serum insulin immunosensor. MWNT-COOH coated electrodes displayed a C=O 
stretching at 1730 cm–1 and an O-H stretching at 3380 cm–1 (Figure 2.4-A). The characteristic C-
H wagging vibration of Py-COOH was observed in Figure 2.4-B at 787 and 840 cm–1.57 With 
immobilization of proteins (i.e., Absurface and BSA), amide-I C=O stretching and amide-II N-H 
bending peaks were observed at 1640 and 1550 cm–1, respectively, along with an N-H stretching 
at ~3500 cm–1.18 Binding of serum insulin from the MNP-AbHRP-insulin conjugate onto the 
surface Ab of MWNT-COOH/Py-COOH/Absurface/BSA increased the intensities of amide-I and 
amide-II signals along with the C=O peak due to the formation of a sandwich immunoassembly 
featuring serum insulin molecules sandwiched between the Absurface and AbHRP. 
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Figure 2.4. FTIR spectra of A. MWNT-COOH, B. after Py-COOH stacking, C. after covalent 
attachment of Absurface, D. after BSA blocking, and E. after binding of MNP-AbHRP-insulin 
conjugate prepared with 150 pM serum insulin concentration. 
 Figure 2.5 illustrates the stepwise Raman characterization of the immunosensor. Figure 
2.5-A shows the characteristic D and G bands of MWNT-COOH that shifted to a lower frequency 
after π-π stacking with Py-COOH molecules.58 The D and G bands shifted from 1354 and 1593 
cm–1 to 1345 and 1588 cm–1, respectively. This was attributed to the partial electron transfer from 
Py-COOH to MWNT-COOH and a relatively weaker C-C bond force constant on the hybrid 
complex than on nanotubes.59 This confirmed that π-π stacking of Py-COOH molecules on the 
MWNT-COOH electrode occurred after the pyrenyl incubation over nanotubes. Figure 2.5-B 
shows the Raman spectra for every modification on the electrode surface. All spectra exhibited 
carbon related D, G, and 2D modes at approximately 1350, 1600, and 2900 cm–1, respectively. 
After binding of the MNP-AbHRP-insulin conjugate (150 pM serum insulin treated) onto the 
surface insulin antibody, a weak phonon band for the Fe3O4 core of MNPs was observed at 
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approximately 150 cm–1. Together, the spectral and microscopic studies confirmed the 
applicability of the designed immunosensor for serum insulin measurements. 
 
Figure 2.5. A. Raman spectra showing the D and G bands of MWNT-COOH shifted to lower 
frequencies after π-π stacking of Py-COOH molecules. B. Raman spectra of i. MWNT-COOH, ii. 
after Py-COOH stacking, iii. after covalent attachment of Absurface, iv. after BSA blocking, and v. 
after binding of MNP-AbHRP-insulin conjugate prepared with 150 pM serum insulin. Inset shows 
the weaker phonon band of magnetite core of MNPs in the MNP-AbHRP-insulin conjugate. 
 
 
 
 
 
 
 
Figure 2.6. Conversion of carboxyl terminals into acyl chlorides and their derivatization with 4-
nitrophenol for assessing electroactive surface coverage in (A) MWNT-COOH only, and (B) Py-
COOH/MWNT-COOH. 
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Electrochemical quantitation of the surface –COOH groups in the two types of 
immunosensors (i.e., with and without Py-COOH) revealed 3.7 (± 0.7) x 10–10 mol/cm2 of -
COOH in MWNT-COOH/Py-COOH modified AuSPEs compared to 0.8 (± 0.1) x 10–10 mol/cm2 
of –COOH in the MWNT-COOH only modified AuSPEs. Quantitation of carboxyl groups was 
done by converting them to acyl chlorides followed by derivatization with 4-nitrophenol via an 
ester linkage.60 This strategy was adopted for both immunosensors with and without π-π stacking 
of pyrenyl compounds (Figure 2.6). The voltammetric reduction of the arylnitro-labels on the 
surface allows for quantitation of carboxyl groups (Figure 2.7 for cyclic voltammograms).60  
 
 
 
 
 
 
 
 
Figure 2.7. Cyclic voltammograms used for the quantitation of surface carboxyl groups based on 
the arylnitro derivative reduction peaks (at ~ -0.8 V) of A. MWNT-COOH/Py-COOH and B. 
MWNT-COOH modified on AuSPEs. This derivative peak is absent on C. bare AuSPE with no 
modification. Inset shows the enlarged view of the derivative peak of MWNT-COOH at ~ - 0.8 V 
(B), which is absent on the bare AuSPE (C). The measurements were done at 23 ˚C in phosphate 
buffer (pH 6.8, 25 mM KH2PO4, 25 mM Na2HPO4), scan rate 75 mV/s.  
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Thus, the higher number of –COOH groups available in the combined MWNT-
COOH/Py-COOH modification (i.e., 4.6-times) could offer greater covalent attachment of 
Absurface molecules than the MWNT-COOH modification alone on AuSPEs, which would result in 
enhanced serum insulin detection sensitivity (Figure 2.8). We quantitated Absurface using the 
NanoOrange Protein Quantitation Kit (Thermo Fisher Scientific). The amount of Absurface on the 
MWNT-COOH/Py-COOH modified AuSPEs was estimated to be 8.7 ± 2.5 pmol/cm2, whereas it 
was 2.9 ± 0.4 pmol /cm2 in the case of only MWNT-COOH modified AuSPEs. This quantitation 
confirmed that the combination of covalent and noncovalent carboxylations of MWNT allowed 
greater amount of immobilized Absurface (about 3 times) compared to MWNT-COOH only 
modified AuSPEs. 
 
Figure 2.8 Strategy to enhance the number of antibodies immobilized in MWNT-COOH (A) by 
π-π stacking Py-COOH over MWNT-COOH (B). 
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2.3.2 Amperometric responses relationship with insulin-magnetic nanoparticles conjugates 
Figure 2.9-A shows the amperometric current signals for various serum insulin concentrations 
detected by the designed immunosensor. The amperometric trace for serum insulin of a 20-times 
diluted T2D patient’s serum in PBS (that corresponds to 5% serum) is also shown in Figure 2.9-
A. From the calibration plot of measured currents with insulin concentration, we determined the 
patient serum insulin concentration to be 340 ± 30 pM, which agreed with estimation by the 
standard enzyme-linked immunosorbent assay (commercial serum insulin kit, Mercodia Inc., 
Sweden) method.17 As mentioned earlier, similar to the above immunosensor design of MWNT-
COOH/Py-COOH/Absurface/BSA on AuSPEs, we designed a sensor without the Py-COOH linkers 
(i.e., MWNT-COOH/ Absurface/BSA on AuSPEs) for serum insulin measurements using the above 
described MNP-AbHRP-insulin conjugation strategy (Figure 2.9-B). Immunosensors without Py-
COOH linkers offered lower current signals as well as a narrower dynamic range compared to 
sensors with Py-COOH linkers.  
Figure 2.9. Immunosensor current signals with increasing serum insulin concentration in 5% 
serum captured onto MNP-AbHRP conjugates and upon binding to surface immobilized insulin-
antibody on A. with and B. without Py-COOH linkers on MWNT-COOH coated AuSPEs. 
Experimental Conditions: - 0.1 V vs. pseudo Ag reference, 1 mM HQ, 0.5 mM H2O2, flow rate 
200 µL/min, room temperature (23 oC), N = 4 replicates. 
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Figure 2.10 (A and B) compares the current responses for different serum insulin 
concentrations measured by the two immunosensor strategies. The slope of the linear relationship 
plots between current and concentration corresponds to sensitivity. From the slopes, we 
determined that AuSPEs fabricated with the π-π stacked Py-COOH molecules on MWNT-COOH 
showed nearly 3-times greater sensitivity compared to those without the Py-COOH molecules 
(Figure 2.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Current responses for immunosensor electrodes fabricated A. with and B. without 
Py-COOH linkers on MWNT-COOH coated AuSPEs for serum insulin detection (N = 4 
replicates).   
The linear range of the designed immunosensor with Py-COOH stacking was from 2-125 
pM and for the sensor without the Py-COOH the linear range was from 5-125 pM serum insulin 
(Figure 2.10). This linear range is sufficient to differentiate type 1 (< 50 pM) from type 2 (> 70 
pM) diabetes serum insulin levels under fasting conditions. The decrease in current signals at 
higher concentrations could have likely risen from the surface saturation of the electrode with 
MNP-AbHRP-insulin conjugates and resulting associated resistance for the communication of the 
electron transfer mediator with the electrode. More importantly, the sensitivity enhancement 
accomplished in this work by the combination of MWNT-COOH with Py-COOH is also 
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significant for diagnostic biosensors that measures elevated or diminished levels of disease 
biomarkers over normal conditions.  
 The limit of detection (LOD)61 for serum insulin was calculated to be 1.5 pM for the Py-
COOH stacked MWNT-COOH immunosensor electrodes and the LOD was 3.0 pM in the case of 
only MWNT-COOH modified immunosensor electrodes with no Py-COOH stacking. In addition, 
we observed better insulin affinity for Absurface on the MWNT-COOH/Py-COOH modified AuSPE 
sensor (calculated apparent electrochemical Michaelis-Menten constant,62 KMapp, was 168 pM) 
than the MWNT-COOH only modified AuSPE sensor (KMapp 270 pM) (Figure 2.11 for 
Lineweaver-Burk plots). This can be attributed to the greater number of available carboxyl groups 
provided by the combination of Py-COOH and MWNT-COOH for enhanced Absurface attachment 
and in turn to more Absurface binding sites for the binding of MNP-AbHRP-insulin conjugates with 
stronger affinity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. Lineweaver-Burk double reciprocal plots relating the changes in the measured redox 
mediator currents with the concentration of bound serum insulin onto Absurface in the designed 
immunosensors: A. with and B. without Py-COOH linkers on MWNT-COOH coated AuSPEs. 
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2.4 Conclusion 
In conclusion, we demonstrated the significance of combining covalent and noncovalent 
functionalization of carbon nanotubes for sensitive immunosensing applications. We applied the 
aforementioned surface chemistry to design and develop a novel amperometric immunosensor to 
measure serum insulin concentrations with diabetes relevant pM concentration levels. The results 
in this study suggest that the covalently functionalized carbon nanostructure-based sensors, drug 
delivery, and catalytic systems can benefit by additional incorporation of noncovalent pyrenyl or 
other similar noncovalent strategies to deliver improved performance. The presented surface 
design methodology is not limited to electrochemical detection because this combined covalent 
and noncovalent carbon nanostructure functionalization strategy can also be used for optical and 
spectral based detection methods and for any enzyme immobilized electrocatalytic applications. 
Similarly, the detection is not limited to serum insulin alone, any other biomolecules and small 
molecules can be also detected in principle utilizing the demonstrated combination of covalent 
and noncovalent functionalization of carbon nanotubes and other related carbon materials. 
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CHAPTER III 
 
 
GRAPHENE MODIFIED SURFACE PLASMON MICROARRAY FOR SENSITIVE 
MEASUREMENT OF SERUM AUTOANTIBODY LEVELS WITH BINDING INSIGHTS 
 
3.1 Introduction 
Diabetes mellitus is a chronic disease that hampers the body’s ability to use glucose and convert it 
to energy. This results in hyperglycemia, which can eventually lead to many fatal complications, 
including cardiovascular disease, neuropathy, and diabetic nephropathy. Due to changing 
lifestyles and environmental causes along with genetic factors, the number of people affected by 
diabetes is on the rise. According to WHO, diabetes was the seventh leading cause of death 
worldwide in 2016.  
Traditionally, diabetes is divided into two categories based on how the body responds to 
insulin, which is a polypeptide hormone secreted in the islets of Langerhans in the pancreas. T1D 
results from genetic and environmental factors and is associated with the destruction of β-cells, 
which leads to insulin deficiency, and is also characterized by the appearance of autoantibodies 
against β-cell antigens namely: glutamic acid decarboxylase-65 (GAD-65), insulin, and tyrosine 
phosphatase-related islet antigen 2 (IA-2).63,64 In contrast, T2D results from the body’s inability 
to use the produced insulin. 
Adapted with permission from Premaratne, G.; Niroula, J.; Patel, M. K.; Zhong, W.; Suib, S. L.; Kalkan, A. K.; Krishnan, S. Anal. 
Chem. 2018, 90, 12456-12463. Copyright (2018) American Chemical Society. 
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Although diabetes is a serious medical condition, it can either be delayed or avoided with early 
prediction and maintenance of a healthy lifestyle. Consequently, it is essential to develop a tool 
that can fundamentally predict the susceptibility of a person to develop the disorder long before 
the clinical onset.   
In recent years, the prevalence of diabetes, in particular T1D, is continuously increasing 
at a rate of 3% every year, and this in turn has impacted the incidence of associated lethal 
complications in children and adults likewise.65 While the etiology of T1D is mostly unknown, a 
combination of genetic predisposition, environmental factors, and a dysfunctional immune system 
is believed to play a significant role in the development of the autoimmune disorder.66- 68 
Numerous studies have reported that serum autoantibodies against the β-cell antigens are present 
in patient’s biological fluids years before the clinical onset of diabetes.69  
In the early 1990s, a 65 kDa autoantigen known as GAD-65 was identified to interact 
with an autoantibody, leading to the discovery of glutamic acid decarboxylase-65 autoantibody 
(GADA). GADA is the first line of clinical assessment in diagnosing the development of T1D, 
and its presence indicates the need for screening of other islet autoantibodies. A positive result for 
three or more autoantibodies suggests that the risk for developing T1D is 100% within the next 5 
years.70 Although the seropositivity for GADA varies with environmental, geographical, ethnic, 
and genetic factors, a general consensus reference value of ≤ 1.3 ng/mL is usually accepted as a 
normal condition.27 Higher concentrations of GADA can indicate susceptibility to autoimmune 
diabetes and other endocrine disorders.  
Over the past two decades, many research groups demonstrated several methods for 
clinical diagnosis of T1D including radioimmunoassay (RIA),71 enzyme-linked immunosorbent 
assay (ELISA),72 chemiluminescent immunoarray (CLIA)73, and electrochemiluminescence 
assay74. These techniques are mostly time consuming (> 2 h), with RIA taking almost 2 days to 
33 
 
complete the analysis of a single autoantibody. Previous studies for GADA on surface plasmon 
resonance (SPR) platform mainly focused on surface modification techniques using self-
assembled monolayer (SAM) of thiols and enzyme precipitation.75- 77 These studies mainly lacked 
in areas of clinical significance. Additionally, a few other studies demonstrated multiplexing of 
autoantibodies using plasmonic, electrochemiluminescence, and ELISA platforms, but most of 
them involved longer assay times and required chemical labels.28-30 In contrast, magnetic beads 
(MAG)-based signal amplification labels are relatively more robust and allow easy conjugation of 
capturing biomolecules and isolation of target analytes, thus minimizing interference from the 
sample matrix in detection signals. In this context, surface plasmon resonance microarray 
imaging (SPRi)-based biosensing devices provide an effective tool for rapid, real-time, sensitive, 
and cost-effective detection of biological analytes in a complex system. SPRi is a label-free 
optical detection technique that provides a suitable and reliable platform for clinical analysis of 
biomolecular interactions and has many applications in biomedical science, bioengineering, 
proteomics, and genomics.78 A SPRi-based diagnostic device is critical for better health 
management of the large diabetic population. It would be suitable for frequent monitoring of 
multiple analytes in a small sample amount (a few microliters of serum).34 
As a novel class of two-dimensional nanocarbon materials, graphene and its derivatives 
have been extensively used in biomedical sciences for the development of electrochemical and 
optical biosensors.79- 81 The high surface area to volume ratio, electrical conductivity, aqueous 
dispersibility, thin structure, and apparent biocompatibility of graphene makes it a unique carbon 
nanomaterial for biorecognition events and biosensing applications.82- 84 Studies have shown that 
using graphene over a thin metal (gold or silver) surface enhances the SPR signals due to charge 
transfer from graphene to the metal, which leads to strong excited electric field enhancement at 
the surface.85 In recent years, graphene has been used extensively alone or with metal composites 
to fabricate ultrasensitive biosensors for the detection of biomolecules, including cancer 
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biomarkers and DNA.86,87 Graphene has great potential in the development of next generation 
biomolecular electronics and spintronic devices due to its electrical, optical, and thermal 
properties.88,89  
In this study, an array-based biosensing device for the detection of GADA directly in 
clinical matrices was fabricated. Additionally, carboxylated graphenyl surface was quantitatively 
compared with the conventional 3-mercaptopropionic (MPA) monolayer surface to obtain 
analytical insights into the assay performance (Figure 3.1). Furthermore, binding parameters were 
also established for the GAD-65 antigen-autoantibody complexes as a quality control checkpoint. 
The knowledge gained from the combined sensing and binding assessment is useful for 
developing reliable, and better throughput clinical immunosensors for biomarker based diagnostic 
assays.  
 
Figure 3.1. Graphenyl and mercapto- based immunosensor designs for comparative analysis of 
GADA detection. 
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This study was one-half of a project where we looked at electrochemical detection of 
serum GADA and correlated it with GADA detection in SPRi platform. The electrochemical part 
of the project was performed by previous group member Gayan Premaratne. 
3.2 Experimental 
3.2.1 Reagents and materials 
8-channel screen-printed gold electrodes (8xSPE) were purchased from DropSens Inc., Spain 
(Product No. 8x220BT). SPR imaging (SPRi) gold array chips (Spot Ready 16, 1 mm diameter 
gold spots) were purchased from GWC Technologies (Madison, WI).  Carboxylated graphene 
(graphene-COOH) was purchased from ACS materials (Medford, MA). Glutamic acid 
decarboxylase-65 antigen (GAD-65) was bought from Creative Diagnostics (Shirley, NY, USA). 
Monoclonal glutamic acid decarboxylase-65 autoantibody (GADA), bovine serum albumin 
(BSA, ≥ 98%), aminoferrocene, 3-mercaptopropionic acid (MPA, ≥99%), 1-ethyl-3-[3-
(dimethylamino) propyl] carbodiimide (EDC), and N-hydroxysuccinimide (NHS) were purchased 
from Sigma (St. Louis, MO). Normal human serum was purchased from Atlanta biologicals 
(Flowery Branch, GA). Human serum samples were diluted 10-times in phosphate buffered saline 
(PBS), pH 7.4. Protein A/G coated magnetic beads (MAG-protein A/G, 2 µm, 10 mg mL-1) were 
purchased from Biotool (Houston, TX). The beads contain 9.3×1013 protein A/G molecules/cm2 
(Biotool). All other chemicals used were analytical grade. The reagents were prepared using 
ultra-pure water (Invitrogen Corporation, Grand Island, NY). All measurements were conducted 
at room temperature (23 ˚C). 
3.2.2 Instrumentation and methods 
SPRi responses were obtained using a GWC SPR imager-II (Horizon SPR imager model). The 
SPR microarray imager was purchased from GWC Technologies (Madison, WI). The 
instrument’s light source had an operating wavelength of 800 nm and had a charge coupled 
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device camera as the detector. The SPR curves were fit for kinetic analysis using TraceDrawer 
Software (Ridgeview Instruments AB, Vänge, Sweden). 
Characterization of each step of the surface modification was conducted by scanning 
electron microscopy (SEM, Model: FEI Quanta 600FE) at an accelerating voltage of 20 kV. The 
images were acquired using FEIxT Microscope Control Software. Additional characterization of 
the sensor designs was conducted by Fourier transform infrared spectroscopy (FTIR, Thermo 
Scientific Nicolet iS50) operated in the attenuated total reflection mode using a diamond crystal. 
XPS analysis of the surfaces of SPRi chip modified with graphene-COOH and MPA 
were performed using a Quantum 2000 Scanning ESCA Microprobe (Physical Electronics, Inc., 
MN) that features a monochromatic Al Kα x-ray source and an x-ray beam diameter of ≤ 100 µm 
( x-ray power ≤ 25 W), an automatic charge neutralization, depth and line profile analyzer, and an 
elemental mapping. The sample species were prepared by oven baking one gold SPRi chip drop-
coated with the aqueous graphene-COOH at 50 ºC for 30 minutes while another gold SPRi chip 
was incubated overnight in MPA solution. 
Raman spectroscopic analysis was performed with WITec alpha300 R confocal Raman 
microscope (WITec Instruments Corp., TN) using a laser power of 0.76 mW. The samples were 
prepared by oven baking the drop-coated aqueous graphene-COOH on a gold array spot of SPRi 
chip or on a glass surface as the non-gold control. 
Cyclic voltammetric measurements were performed using a CHI 1040C electrochemical 
workstation (Austin, TX). Cyclic voltammetry was used for the quantitation of surface carboxyl 
groups of graphene-COOH and MPA by aminoferrocene derivatization of the –COOH groups.   
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3.2.3 Preparation of SPRi immunosensor 
Figure 1 shows the schematic representation of the SPR immunosensor designed in this study. 
Prior to use, the SPRi gold array chip was cleaned in piranha solution (3:1 mixture of 
concentrated H2SO4 and 30% H2O2 for 10 seconds (Caution: Piranha solution is highly corrosive 
and a strong oxidizer)).  
First, 0.30 µL of 0.1 mg/mL of carboxyl-functionalized graphene (graphene-COOH) was 
dry-coated on each gold spot of the SPRi chip and dried at 50 °C for 30 minutes. The chip was 
then washed thoroughly with water to remove any unbound molecules. Following dry-coating, 
the terminal carboxyl groups of carboxylated graphene were activated by converting them into N-
succinimidyl esters after incubating it with 100 µL of a freshly prepared mixture of 0.4 M EDC 
and 0.1 M NHS in ultrapure DI water for 15 minutes. These esters facilitated covalent attachment 
of lysine residues from the GAD-65 autoantigen after incubating the chip with 100 µL of 100 nM 
GAD-65 prepared in PBS buffer for 30 minutes. After autoantigen immobilization, the surface 
was blocked with 100 µL of 1 % BSA in PBS for 30 min to minimize nonspecific binding. Then 
each spot was individually incubated with 0.25 µL a different concentration of 1 mg/mL MAG-
protein A/G-autoantibody conjugate and the corresponding change in pixel intensity was 
observed. The chip was then mounted in the SPRi instrument to monitor real-time reflectivity 
changes upon the binding of various concentrations of serum GADA captured onto MAG-protein 
A/G beads. Once the steady state response was reached, the SPR chip surface was rinsed well 
with PBS (pH 7.4) to remove any unbound molecules present in the bulk solution and attain a 
new baseline signal. Similar SPR measurements were taken for an immunosensor prepared with a 
self-assembled monolayer of MPA instead of the graphene-COOH modification. 
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3.2.4 Preparation of magnetic bead-protein A/G-autoantibody conjugates (MAG-protein 
A/G-GADA) 
MAG beads functionalized with surface protein A/G molecules offer binding sites with 
orientation for capturing antibodies from serum. The capturing procedure followed the 
instructions provided by the manufacturer with slight modifications. In brief, 25 µL of MAG-
protein A/G bead was washed twice with 150 µL of phosphate buffered saline (PBS, pH 7.4, 10 
mM phosphate, 0.14 M NaCl, 2.7 mM KCl), and separated out using a small piece of magnet 
after each wash. Then the beads were washed twice in 150 µL of binding buffer (50 mM tris, 150 
mM NaCl, 0.1% Tween 20, pH 7.5). Different concentrations of GADA spiked in 10% normal 
human serum in the binding buffer (250 µL) were added to separate aliquots of MAG-protein 
A/G beads and rotated in a tube rotor (Fisher scientific) for 1 h at room temperature.  Upon 
completion of the incubation, the contents were suspended by pipetting in and out for 10 times, 
and the supernatant was removed immediately from the magnetically separated beads. The beads 
were washed two times with 300 µL of the binding buffer. Finally, the beads were suspended to a 
final volume of 200 µL in the binding buffer. The MAG-protein A/G captured serum GADA 
samples were stored at 4 oC and used for up to 5 days.  
3.2.5 Quantitation of surface carboxyl groups based on electroactive aminoferrocene labels 
8xSPEs were dry-coated with graphene-COOH or with a self-assembled monolayer of MPA (one 
8xSPE was used for each modification) followed by carbodiimide activation of the surface 
carboxyl groups using the 0.4 M EDC and 0.1 M NHS solution mixture. Then a 4.5-µL solution 
of 1 mM aminoferrocene in PBS, pH 7.4 was placed on the –COOH activated electrodes and 
incubated for 45 min in a cold and moist atmosphere. To ensure the covalent strategy of linking, 
we prepared graphene-COOH or MPA modified 8xSPEs with an electrostatically adsorbed layer 
of aminoferrocene. Then the electrodes were rinsed with deionized water to remove any unbound 
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molecules. Cyclic voltammograms (CVs) were recorded to calculate the electroactive 
aminoferrocene molecules, and in turn the relative amounts of –COOH groups on graphene-
COOH and MPA surfaces. 
3.3 Results and discussion 
3.3.1 Assessment of plasmonic enhancement property of the graphene-gold complex 
To illustrate the plasmonic enhancement property of graphene-COOH on the Au surface of the 
designed sensor,90 we performed Raman spectral analysis of the graphene-COOH coated on the 
gold surface of a SPRi chip and compared the spectral peak intensity with similarly coated 
graphene-COOH on a plain glass instead of gold (Figure 3.2). The Raman signal for the D band 
at ~1350 cm-1 and G band at ~1600 cm-1 shows about 5.5-times signal enhancement for graphene-
COOH coated on the Au surface compared to the glass substrate. The increase in Raman signals 
has been proposed to be due to a charge-transfer process from the graphenyl material to the gold 
metal surface resulting in the coupling of metal plasmons with graphene plasmons and the 
associated enhancement of electromagnetic fields.86, 91 
 
 
 
 
 
 
Figure 3.2. Raman spectra for graphene-COOH dry coated on (a) glass or (b) gold surface of an 
SPR chip.  
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3.3.2 Immunosensors characterization 
The SEM images acquired at each step of the immunoassembly are presented in Figure 3.3 – A to 
D. Figure 3.3-A shows the image for a rough Au surface. Dry coating of graphene-COOH on the 
Au surface resulted in spherical mesh-like and thread-like features (Fig. 3.3-B).92 The graphene 
surface feature became denser upon the covalent immobilization of GAD-65 antigen followed by 
blocking with a solution of 1% BSA in PBS (Fig. 3.3-C). After the binding of the MAG-protein 
A/G-GADA conjugate onto the surface GAD-65 sites, the appearance of spherical MAG bead 
features on the electrode surface can be seen (Fig. 3.3-D). 
 
 
 
 
 
 
 
 
Figure 3.3. SEM images of A. rough Au surface, B. after dry coating of an aqueous suspension of 
graphene-COOH, C. after covalent attachment of GAD-65 antigen and surface blocking with 1% 
BSA, and D. after the binding of GADA spiked in 10% human serum and captured onto MAG-
protein A/G beads. 
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FTIR spectra further confirmed the results obtained from the SEM image analysis. The 
bare Au surface did not show any significant peak in the measured vibrational region of the IR 
spectrum (Figure 3.4-A). Upon coating with graphene-COOH (Figure 3.4-B), the appearance of a 
strong and broad peak at about 3219 cm-1 was attributed to the hydroxyl vibration of the surface 
carboxyl groups.93 Additionally, the peaks at 1719 cm-1 and 1078 cm-1 are characteristics of the 
stretching vibrations of carboxylic acid and other surface carbonyl groups.94 Upon activation of 
the surface carboxyl groups using EDC/NHS chemistry, the characteristic decrease in the O-H 
stretching vibration was observed (Figure 3.4-C). Additionally, new peaks centered at 1764 and 
1043 cm-1 corresponding to the C=O and C-O stretching vibrations of the succinimidyl esters 
from the EDC/NHS modification were present.95,96   
The protein amide-I at 1639 cm-1 and amide-II at 1547 cm-1 were observed due to the 
formation of amide bonds after the covalent attachment of the GAD-65 antigen with the 
graphene-COOH surface (Figure 3.4-D).97 In addition, a new peak at 3324 cm-1 indicated the N-H 
stretching vibration of the protein. When the serum GADA carried by the MAG-protein A/G 
beads bound to the surface GAD-65 antigen, a new peak appeared at 602 cm-1 that was assigned 
to the Fe-O stretching of Fe3O4 magnetic beads (Figure 3.4-E).98 Furthermore, a slight shift in the 
amide-I and amide-II bands was possibly the result of complexation of GAD-65 with GADA. 
Additionally, the N-H bending vibration peak at 794 cm-1 became more prominent due to the 
overall increase in the total protein molecules on the surface as the result of GADA-GAD 65 
immunoassembly formation. 
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Figure 3.4. FTIR spectra of A. rough gold 8xSPE, B. after dry-coating with graphene-COOH, C. 
after EDC/NHS activation, D. after GAD-65 immobilization, and E. after the binding of 5 ng- 
mL-1 concentration of 10% serum GADA captured by the MAG-protein A/G beads.   
The C1s region in the XPS spectra of graphene-COOH coated or MPA monolayer on the 
gold surface are presented in Figure 3.5. The XPS data were analyzed for carbon atoms from 
different functional groups such as C-C at 284.8 eV, C-O in epoxy/ether at ~286.0 eV, and C=O 
at ~288.0 eV.99,100 As expected, the carboxyl groups on the graphene-COOH surface are greater 
than the MPA modified gold surface, which would thus provide greater sites for covalent 
attachment of GAD-65 antigen via amide bonds. The XPS finding correlated well with the 
electroactive quantitation of surface–COOH linked aminoferrocene molecules as discussed 
below. 
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Figure 3.5. XPS spectra in the C1s region of A. Graphene-COOH coated gold SPR chip, and B. 
self-assembled monolayer of MPA on a gold SPR chip. 
3.3.3 Estimation of the relative surface carboxyl groups on graphene-COOH and MPA 
modified gold surfaces 
Figure 3.6-A and B represents the cyclic voltammograms of the graphene-COOH and MPA 
electrodes with covalently attached and electrostatically adsorbed redox active aminoferrocene 
molecules (voltammograms-a and b in each plot respectively). Integrated peak areas are directly 
proportional to the amount of electroactive aminoferrocene molecules bound to either graphene-
COOH or MPA surface. The average formal potentials of the covalently attached aminoferrocene 
film on the graphene-COOH and MPA surfaces were 112 ± 5 and 114 ± 8 mV, respectively. The 
electrostatically adsorbed films of aminoferrocene on each of the modified surfaces exhibited a 
similar formal potential as the covalent films. However, the covalent films enabled higher 
electroactive aminoferrocene immobilization than the electrostatic films. 
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Figure 3.6. Background subtracted CVs of A. graphene-COOH, B. MPA modified gold 
electrodes with a. covalently attached, and b. adsorbed films of aminoferrocene in argon purged 
PBS buffer, pH 7.4, 23 °C. The scan rate was 0.1 V s−1. 
From the oxidation peak area, the electroactive surface coverage (Г, Equation 3.1) of 
aminoferrocene and in turn, the relative amount of carboxyl groups were determined.101 Q is the 
area of the oxidation peak of aminoferrocene, n is the number of electrons involved in the 
aminoferrocene oxidation (n = 1), F is the Faraday’s constant, and A is the area of the working 
electrode (A = 0.2 cm2). 
Г = Q / (nFA)   (Equation 3.1) 
Graphene-COOH surface provided a 9-fold greater surface carboxyl groups than the MPA 
monolayer surface for the covalent films (Table 3.1). 
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Table 3.1. Relative estimation of electroactive amounts of aminoferrocene on graphene-COOH 
and MPA modified electrodes.  
 
 
 
 
 
 
 
3.3.4 Electrochemical detection of serum GADA concentrations 
The identical immunosensing strategy was used to detect serum GADA concentrations in an 8-
channel screen-printed gold electrodes (8xSPE) electrochemical array using faradaic 
electrochemical impedance spectroscopy (EIS). Faradaic impedance measurements for various 
concentrations of MAG-protein A/G captured serum GADA (10% normal human serum) bound 
onto GAD-65 were performed at room temperature (23 oC) in an aqueous electrolyte solution 
containing 0.1 M KCl and 10 mM each of Fe(CN)63-/Fe(CN)64- as the redox probe. A potential of 
0.2 V vs. a pseudo Ag reference electrode was applied at an AC amplitude of 10 mV, and the 
frequency was scanned from 100,000 – 100 Hz. The experimentally obtained Nyquist plot data 
were fit by the Randles equivalent circuit model to determine the charge transfer resistance (Rct) 
values. 
The Faradaic impedance responses and the respective calibration plots are presented in 
Figure 3.7-A to D. The Rct of GAD-65 sensor surface increased with the binding of increasing 
Parameter Graphene-COOH MPA 
Covalently 
attached 
aminoferrocene 
labels 
Q (nC) 920.3 ± 86.6 98.1 ± 5.9 
Calculated Г 
(pmoles/cm2) 47.6 ± 5.1 5.1 ± 0.3 
Adsorbed 
aminoferrocene 
labels 
Q (nC) 189.4 ± 15.4 31.0 ± 1.9 
Calculated Г 
(pmoles/cm2) 9.8 ± 1.3 1.6 ± 0.11 
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serum GADA concentration (10% serum in PBS) captured with the MAG-protein A/G beads. The 
detection sensitivity enhancement by the graphene-COOH modification compared to a 
conventional self-assembled monolayer surface on gold was also studied using MPA modified 
surface. 
The results obtained indicated that the graphenyl sensor displayed a wider dynamic range 
of 0.02–2 ng mL−1 and several thousands of increased Rct values over the MPA monolayer 
modified sensor (0.04–0.75 ng mL−1) for the same GADA concentration. A sensitivity 
enhancement of about 3-fold was observed for the graphenyl surface over the MPA modified 
surface. 
 
 
 
 
 
 
 
Figure 3.7. Nyquist plots for the Faradaic impedance measurements in an aqueous solution 
containing 0.1 M KCl and 10 mM each of Fe(CN)63-/Fe(CN)64- for various concentrations of 
surface bound serum GADA immunoassembly on: A. graphenyl (a. 0.02, b. 0.05, c. 0.1, d. 0.25, 
e. 0.5, f. 0.75, g. 1.0, and h. 2.0 ng mL-1) and B. MPA (a. 0.02, b. 0.05, c. 0.1, d. 0.25, e. 0.5, and 
f. 0.8 ng mL-1) modified immunosensors. C and D represent the calibration plot of respective 
response plots for Rct changes with concentration of GADA. (N = 3 replicates.)  
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3.3.5 SPRi pixel intensities for various serum GADA concentrations 
The low dielectric permittivity and intrinsic graphene plasmonics with the ability to modulate the 
evanescent wave92,102 allowed us to construct the immunosensor assembly on an SPR gold array 
chip to detect serum GADA and additionally obtain binding kinetic parameters. Increase in SPRi 
pixel intensities with increased concentration of serum GADA for graphene-COOH and MPA 
modified immunosensors are illustrated in Figures 3.8 -A and B, respectively. The nonspecific 
binding signal for MAG-protein A/G treated serum with no spiked GADA was taken as the 
control response. The control signal was lower for the graphene-COOH sensor compared to the 
mercapto modified sensor demonstrating that BSA blocked graphene-COOH surface is better 
than the conventional gold-MPA surface to minimize nonspecific signals. The results confirm 
that the assay specificity is based on the selective GADA and GAD-65 interaction. 
Figure 3.8. SPRi pixel 
intensities for different 
concentrations of serum 
GADA captured by 
MAG-protein A/G beads 
and bound onto GAD-65 
antigen immobilized on 
A. graphene-COOH and 
B. MPA modified gold 
array chip. Control 
responses in A and B correspond to signals for the binding of 10% serum treated with MAG-
protein A/G beads without spiked GADA. C. Control subtracted SPRi response plots with 
concentration of serum GADA for the GAD-65 immobilized graphene-COOH or MPA surface. 
(N = 4 replicates.) 
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Figure 3.8-C illustrates the linear range of SPRi response plots for varying concentrations 
of 10% serum GADA captured onto MAG-protein A/G beads and bound to the surface 
immobilized GAD-65 on both graphene-COOH and MPA surface. Graphene-COOH modified 
sensor was almost 2-times more sensitive than the MPA modified sensor. For the graphene-
COOH sensor, the SPRi dynamic range was 0.01–1.25 ng mL−1 with 3-times lower detection 
limit (6.5 pg mL−1) than the MPA sensor with a dynamic range of 0.01–1.00 ng mL−1 and a 
detection limit of 18.8 pg mL−1.  
3.3.6 Determination of kinetic parameters from the real-time binding of surface 
immobilized GAD-65 with MAG-protein A/G beads captured serum GADA 
The kinetic analysis103 was performed for the biomolecule interaction by assuming a 1:1 binding 
reaction as detailed below: 
A+B ⇌  AB       (3.2) 
Rate of association: d[AB]
dt
= ka[A][B]- kd[AB]  (3.3) 
Rate of dissociation: d[AB]
dt
= - kd[AB]   (3.4) 
Where, A is the GAD-65 antigen immobilized on the SPR chip, B is the GADA captured MAG-
protein A/G beads, and AB is the antigen-antibody complex formed. Since the concentration of A 
is constant, the antigen-antibody complex formation is considered to follow a pseudo first order 
kinetics, where the SPR responses of the interaction with time is given as: 
dR
dt
= kaCRmax- (kaC+ kd)Rt     (3.5) 
The integrated form of (3.5) is given as: 
Rt= 
kaCRmax�1-e-�kaC+ kd�t�
kaC+ kd
+ R0    (3.6) 
49 
 
KD
app= kd
ka
       (3.7) 
Where, Rt and Ro are the SPR responses at any time t and at t=0 respectively, Rmax is the 
maximum reflectivity change, C is the concentration of serum GADA captured onto MAG-
protein A/G beads, ka is the apparent association rate, kd is the apparent dissociation rate, and 
KD
app is the apparent binding constant. The values of ka and kd were obtained by fitting the 
experimental SPR curves using the TraceDrawer kinetics software (Figure 3.9). 
 
 
 
 
 
Figure 3.9. Simulated (red) and real-time SPR sensograms (black) representing different 
concentrations (a to c) of 10% serum GADA, 0.05, 0.10, and 0.50 ng/mL, captured with MAG-
protein A/G beads and bound onto GAD-65 immobilized sensor surfaces modified with A. 
graphene-COOH and B. MPA.  
 The kinetic parameters comprising association rate (ka), the dissociation rate (kd), and the 
binding constant (KD) for both graphenyl and mercapto surfaces are presented in Table 3.2. 
 
50 
 
Table 3.2. Kinetic parameters for the MAG-protein A/G beads captured serum GADA binding 
onto a SPRi surface immobilized with GAD-65 antigen. 
 
 
 
 
 
The lower KD value for the graphene-COOH modified SPRi chip suggests that graphene 
provides a stronger GADA-GAD-65 binding interaction platform through its increased number of 
surface carboxyl groups and plasmon enhancing feature when compared to the mercapto 
monolayer modified chip. Moreover, the KD values of both MPA and graphene-COOH modified 
chips are smaller (i.e., better affinity) in comparison to the previously reported SPR assay value 
(KD = 1.37 nM) in PBS buffer medium on the surface of a mixed self-assembled monolayer.104 
This is possible due to the signal enhancements from the MAG-protein A/G bead strategy 
offering a highly enhanced signal output than free GADA present in solution. Moreover, MAG-
bead based strategy was shown to allow a significantly greater amount of immobilization of 
surface antibodies due to the large number of particles with the net high surface area.105 The high-
density antibody carrying MAG-beads are expected to facilitate a greater rate of association with 
surface immobilized GAD-65 molecules and a slower dissociation when the interactions are 
strong (Table 3.2). A previous report estimated that over 100,000 molecules of antibody can be 
bound selectively to MAG-beads (1 µm) that facilitated attomolar detection limits of prostate 
specific antigen.55 
 
Kinetic parameters Graphene-COOH MPA 
Association rate 
constant, ka [M-1 s−1] 
1.05 (± 0.13) × 109 0.90 (± 0.13) × 109 
Dissociation rate 
constant, kd [s−1] 
3.2 (± 0.4) × 10−3 5.0 (± 0.6) × 10−3 
Binding constant, KD 
[pM] 3.0 ± 0.5 5.6 ± 1.0 
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3.4 Conclusion 
Here, we presented an SPR immunoarray that can detect low levels of GAD-65 autoantibody in a 
serum matrix. The SPR microarray imager provided detection of the autoantibody-autoantigen 
interaction without the need of any chemical or enzymatic detection labels. The detection was 
based on the use of MAG-protein A/G bead-based signal amplification, which also allowed easy 
isolation and separation of serum autoantibody for detection in the antigen array. Additionally, 
MAG beads offered better sensitivity and selectivity of the autoantibody analyte signal compared 
to control serum samples. In comparison, plasmon enhancing graphene-COOH sensor offered 
higher sensitivity and selectivity with wider detection window than MPA sensor for GAD-65 
autoantibody detection. The application of large surface area graphene for high density covalent 
attachment of GAD-65 enabled us to achieve a low detection limit of 6.50 pg/mL of GAD 
autoantibody. Additionally, graphene-based sensor offered higher specificity by reducing the 
background signals. This SPR microarray methodology is an attractive and promising tool for 
reliable diagnostics and early prediction of T1D based on autoantibody levels. The binding 
constant parameter can be used as a quality control checkpoint for large-scale production of 
graphenyl biosensors to implement for reliable applications in clinical diagnostic assays. 
Furthermore, the microarray surface design and detection strategy presented would be suitable for 
measuring any other serum biomarkers of significance present in clinical matrices.  
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CHAPTER IV 
 
 
PAPER-BASED LABEL-FREE NON-FARADAIC IMPEDANCE AGAINST ENZYME 
CORRELATED AMPEROMETRIC SENSOR FOR SMALL MOLECULE DIABETIC 
INSULIN DETECTION 
 
4.1 Introduction 
A “biological marker” or a biomarker is a molecule that can be an indicator of normal versus 
abnormal condition and can help in disease diagnosis and health monitoring.106 It has a broad 
applicability in areas of early diagnosis, disease prognosis, and monitoring clinical response to a 
therapeutic intervention. The field of biomarker study is so widespread that there are numerous 
studies dedicated to identification of biomarkers in different clinical matrices for various diseases 
ranging from Parkinson’s, Alzheimer’s, cancer, diabetes, and many others.107 -110 While, there are 
several studies dedicated to design of sensors for detection of such biomarkers in different 
biological matrices, very few of these sensors are successfully translated into medical devices. 
The shortcomings of such sensors are in the areas of selectivity, specificity, limit of detection, 
dynamic range, reproducibility, and non-specific bindings due to complex biological matrices.111-
113 This gets even more complicated whenever low molecular weight markers with ultralow 
concentrations in biological matrix are to be detected.  
We chose one such molecule in this study as a model system, which is measuring 
picomolar concentrations of insulin in human serum relevant to pancreatic disorders. Insulin is a 
53 
 
small globular protein with two chains: the A chain has 21 residues and the B chain has 30 
residues which are connected to each other by two disulfide bridges and has a molecular weight 
of 5808 Da.114 In this paper, we will use insulin as our “small biomolecule model” to demonstrate 
paper-based electrochemical platform for both label-free and labeled detection of serum insulin 
molecules with clinically significant dynamic range and limit of detection.  
Prior studies, including the ones from our research group, have extensively investigated 
the detection of insulin molecules in both electrochemical and optical platforms.20,115,116 However, 
in the past few years the paradigm has shifted towards label-free detection including direct 
oxidation of insulin molecules.21,117,118 This label-free strategy of biomolecules detection aligns 
with the guidelines for selecting a diagnostic tests set by the World Health Organization.119 In this 
study, in lieu of expensive labeled detection techniques, we are presenting a paper-based label-
free detection strategy of serum insulin molecules using non-faradaic impedance spectroscopy as 
denoted in Figure 4.1. Carboxylated graphene is dry coated on the working electrode which is 
used to immobilize aptamers produced against insulin, which in turn can selectively bind to 
insulin molecules in the serum samples. Capacitance is measured before and after the binding of 
insulin molecules and is represented as the relative changes as the detection signals. The 
capacitance (C) of a double layer interface is given by Equation 4.1. 
C= ε0εrA
d
  (Equation 4.1)  
Here, ɛ0 and ɛr are the permittivity of free space and the dielectric constant of the material 
between the electrode and the mobile charges respectively, A is the surface area of the electrode, 
and d is the distance between the electrode and the mobile charges.120 Hence, the capacitance 
changes when the distance or dielectric properties in the material between the electrode and 
mobile charges changes. 
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Figure 4.1. Paper electrode design with dimensions along with sensor surface modification 
strategy for capacitive detection of serum insulin. 
Graphene is a novel class of two-dimensional carbon nanomaterial of significant interest 
in the scientific community due to its high surface area, high conductivity, high elasticity, and 
rapid electron transfer rates.121,122 Graphene has found prominence in both electrochemical and 
optical sensing for biomolecule detection and signal amplification techniques, and in energy 
storage.123- 126 In relation to this study, we selected carboxylated graphene more specifically due 
to increased biomolecule immobilization sites, aqueous dispersibility, and biocompatibility.127 
Aptamers are single stranded oligonucleotides synthesized by SELEX (Systematic 
Evolution of Ligands by Exponential Enrichment) that can fold into 3-dimensional shapes 
capable of binding non-covalently with an analyte with high specificity, stronger affinity, and 
longer stability, and are convenient in synthesis when compared to antibodies.128,129 Upon 
recognition of binding analyte, they undergo a conformational change thus creating a specific 
binding site for that particular analyte. This folding can result in different kinds of structures such 
as stems, loops, bulges, knots, triplicates, hairpin, and G-quadruplex structures.130 Analogous to 
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an antibody-antigen interaction, the nucleobases of the aptamers exhibit intermolecular 
interactions with the aromatic compounds of the target molecules along with additional 
electrostatic interactions and hydrogen bonding.131- 133 
Furthermore, we also have validated the applicability of the designed immunosensor 
assembly using enzymatic labels and monitoring amperometric signals as shown in Figure 4.2. 
This experimental technique is similar to one of our prior studies using screen printed electrodes 
as demonstrated in Chapter II.134 The paper assembly is similar to the one used in capacitive 
sensing however, after insulin incubation, HRP labeled second insulin antibody is incubated on 
the sensor surface for another 30 min. After washing the electrode, thus prepared sensor is 
connected to a potentiostat and monitored for current signals while applying -0.1 V and adding 
200 µL of a mixture of 1 mM hydroquinone and 0.5 mM H2O2. This study is different from our 
above mentioned prior study in that it uses paper substrate as the electrode setting and does not 
uses pump to flow the mixture of hydroquinone and H2O2 over the sensor surface. 
 
 
 
 
 
 
Figure 4.2. Paper electrode design similar to capacitive sensor with the exception of detection 
strategy using HRP labeled second insulin antibody and monitoring amperometric currents.  
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4.2 Experimental 
4.2.1 Reagents and materials 
GE Healthcare Whatman Grade 1 Chr Cellulose Chromatography Paper was purchased from 
Fisher Scientific (Hampton, NH). Graphite and Ag/AgCl ink were purchased from Ercon Inc. 
(Wareham, MA). Candle wax was purchased from a local Walmart supermarket. Carboxylated 
graphene was obtained from ACS Material, LLC (Pasadena, CA). N-(3-Dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC), N-hydroxysulfosuccinimide (NHS), bovine serum 
albumin (BSA), ethanolamine (EtOH-NH2), aminoferrocene, hydrogen peroxide solution (H2O2), 
and hydroquinone (HQ) were purchased from Sigma-Aldrich (St. Louis, MO). Aptamers for 
insulin were purchased from Integrated DNA Technologies (Coralville, IA). The insulin aptamers 
were C6 amino modified (AmMC6) at the 5' terminal and the sequence was: 5' AmMC6/GGT 
GGT GGG GGG GGT TGG TAG GGT GTC TTC 3'. Recombinant human insulin (> 99%) was 
purchased from Kerafast, Inc. (Boston, MA). Horseradish peroxidase (HRP)-labeled rabbit 
polyclonal anti-insulin antibody (AbHRP) was purchased from LifeSpan BioSciences, Inc. (Seattle, 
WA).   Insulin depleted human serum was purchased from Fitzgerald Industries International Inc. 
(Acton, MA).  A diabetic patient serum sample was purchased from BioIVT (Westbury, NY).  
Ultrasensitive Insulin Enzyme-linked Immunosorbent Assay (ELISA) kit was purchased from 
Mercodia AB (Uppsala, Sweden). Phosphate buffered saline (PBS, 10mM, pH 7.4) was used to 
rinse electrodes and for electrochemical measurements. 
4.2.2 Instrumentation 
Cyclic voltammetric and amperometric measurements were performed on CHI 6017E 
Electrochemical Analyzer (CH Instruments, Austin, TX). Electrochemical impedance 
spectroscopy (EIS) measurements were performed on Interface 1000 Potentiostat (Gamry 
Instruments, Warminster, PA). Stepwise characterization of the sensor surface was performed 
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using Nicolet iS50 Fourier Transform Infrared Spectrometer (ThermoFisher Scientific, Waltham, 
MA). ELISA estimation of serum insulin measurements were performed using a BioTek Synergy 
H1 Plate Reader (BioTek Instruments, Winooski, VT). 
4.2.3 Preparation of paper electrodes 
To design the paper electrodes, Whatman Grade 1 chromatographic paper was cut in 5 cm x 3.2 
cm strips. Electrode connections for working and counter electrodes (WE and CE) were prepared 
by hand drawing graphite ink on the paper substrate. Ag/AgCl ink was used to prepare the 
reference electrode (RE). The WE comprised a circular base of 5 mm diameter. Each of the 
electrodes were 3.8 cm x 0.2 cm. A circular hydrophilic region of 1.2 cm diameter encompassing 
all three electrodes was used as the reaction zone. All other regions of the paper was patterned 
with wax by first coating it with wax and melting it on a hot plate at 150 ˚C for 1 min to allow the 
wax to penetrate across the paper substrate allowing the formation of hydrophobic region.   
4.2.4 Design of immunosensor surface and electrochemical measurements 
Aqueous carboxylated graphene (graphene-COOH, 30 µL of 1 mg mL-1) was drop-casted on the 
base of the WE. After air drying for approximately 6 h, the electrode was cleaned with water air 
dried. A mixture of 0.4 M EDC and 0.1 M NHS (30 µL) was added onto the electrode surface for 
10 min to activate the COOH terminals of the carboxylated graphene. The electrode was then 
rinsed with PBS and incubated with 30 µL of amine functionalized insulin aptamers (30 µM in 
TE buffer, pH 7.5) for 50 min. The activated carboxyl terminals covalently bonded with amine 
terminals on the aptamers through the formation of the amide bonds. The electrode was rinsed to 
remove any unbound molecules and incubated with 20 µL of 1% BSA in PBS for 30 min to cover 
open regions on the electrode as well to deactivate unbound carboxyl terminals. After rinsing the 
electrode, it was again incubated with 20 µL of 10 mM ethanolamine in PBS for 30 min to cover 
the electrode region as well as create insulating layer on the electrode surface. At this point, after 
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rinsing the electrode, the capacitance was measured by EIS for label-free detection. The EIS 
measurements were performed by connecting the paper electrode to the Gamry potentiostat and 
scanning frequency from 100,000 – 0.5 Hz while applying 10 mV AC magnitude and 0 V DC 
potential. The capacitance was monitored at 10 Hz. 
 Different concentrations of insulin-spiked 10% serum sample (50 µL each) was added 
onto the electrode surface for 30 min to allow the insulin molecules in the sample to bind to 
aptamers on the sensor surface. The electrode was rinsed and capacitance was measured again to 
monitor the change in capacitance after insulin binding.  
 For amperometric measurements, after incubation with serum insulin sample and rinsing, 
the electrode surface was further incubated with 50 µL of 1 µg mL-1 HRP-labeled polyclonal anti-
insulin antibody (AbHRP) for 30 min. The electrode was then rinsed and connected to a 
potentiostat. A mixture of 1 mM HQ and 0.5 mM H2O2 (200 µL) was added onto the surface and 
amperometric signals were monitored by applying a potential of -0.1 V. 
4.2.5 Immunosensor optimization and characterization 
The optimum concentration of aptamer immobilized on the sensor surface was determined using 
the faradaic impedance spectroscopic measurements. After the immobilization of 30 µL of 
different concentrations of aptamers on different paper electrodes, they were rinsed and immersed 
in an aqueous solution containing 0.1 M KCl and 10 mM Fe(CN)63-/Fe(CN)64-. A potential of 150 
mV versus a pseudo Ag/AgCl reference electrode was applied at an AC amplitude of 10 mV and 
was scanned in the frequency range of 100,000 – 0.5 Hz. The resulting impedance curves were fit 
by the Randles equivalent circuit model to determine the charge transfer resistance (Rct) values.   
Each individual modification step on the sensor surface was characterized by FTIR 
spectroscopy operating in the attenuated total reflection mode using a diamond crystal. The FTIR 
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spectroscopy allowed the identification of functional vibrations on the stepwise assembly of the 
immunosensor. 
To estimate the number of relative carboxyl groups on the electrode surface after dry 
coating graphene-COOH solution, the electrodes were first activated by treating them with 0.4 M 
EDC/0.1 M NHS. Then, 30 µL of 1 mM aminoferrocene in PBS, pH 7.4, was added to the 
activated surface and incubated for 45 min to allow the immobilization of aminoferrocene on the 
electrode surface through the formation of amide bonds. After rinsing the electrodes to remove 
any unbound molecules, cyclic voltammograms were obtained to analyze the electroactive groups 
on the electrode surface. 
4.3 Results and discussion 
4.3.1 Aptamer concentration optimization 
 
 
 
 
 
Figure 4.3. (A) Faradaic impedance spectroscopy for different concentrations of aptamer 
immobilized on graphene-COOH electrode. (B) Charge transfer resistance (Rct) obtained by 
fitting the corresponding curves to Randles equivalent circuit for different concentrations of the 
insulin aptamer. The red dashed-circle denotes the 30 µM concentration chosen as the optimum 
aptamer concentration. (N=3 replicates.) 
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 The optimum concentration of immobilized aptamer on the sensor surface was 
determined through faradaic EIS as illustrated in Figure 4.3. Figure 4.3-A shows the Nyquist 
plots for different concentrations of aptamer immobilized on separate paper electrodes. These 
plots were fit in Randles equivalent circuit model to obtain the Rct values. The Rct values 
corresponds to the diameter of the semi-circle in the Nyquist plots. The plot of Rct versus different 
concentrations of aptamers (Figure 4.3-B) allowed us to identify the optimum concentration of 
the insulin aptamers on the sensor surface which was 30 µM. Once this optimum concentration 
was established, further modifications on the electrode surface were performed by keeping the 
concentration constant throughout the entire study. 
4.3.2 Immunosensor characterization and carboxyl group estimation 
 
  
 
 
 
 
 
Figure 4.4. FTIR characterization of the stepwise assembly of the immunosensor; (A) bare 
graphite electrode, (B) after graphene-COOH coating, (C) after aptamer immobilization, and (D) 
after double blocking of the surface and insulin capturing via aptamers.  
Figure 4.4 illustrates the stepwise FTIR characterization of the sensor surface after each 
modification step. The bare graphite electrodes did not show any significant peaks. However, 
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after graphene-COOH coating, a broad peak was seen at about 3200 cm-1 that was attributed to 
the hydroxyl stretching, and a peak at 1715 cm-1 was attributed to C=O stretching. Upon binding 
of insulin aptamers, amide I and amide II peaks were observed at 1610 and 1560 cm-1 
respectively, along with N-H stretching at about 3260 cm-1. A peak at about 2935 cm-1 was more 
pronounced and was attributed to heterocyclic bases of the single stranded DNA aptamer. The 
same peaks remain prominent after double blocking and insulin immobilization step. 
 
 
 
 
 
Figure 4.5. (A) Representation of the labeling of carboxylated graphene with aminoferrocene 
molecules through formation of amide bonds. (B) Cyclic voltammograms of (a) bare graphite and 
(b) graphene-COOH coated paper-based electrode with covalently attached aminoferrocene in 
argon-purged PBS, pH 7.4, at 23 ºC at a scan rate of 0.1 V s-1. 
Estimation of the relative carboxyl groups on the bare graphite paper-electrode and 
graphene-COOH coated graphite paper-electrode were determined by cyclic voltammograms of 
redox active aminoferrocene labels covalently attached to carboxyl terminals through the 
formation of amide bonds (Figure 4.5-A,B). The integrated peak area correlated to the amount of 
electroactive aminoferrocene molecules bound to the surface. The oxidation peak area was used 
to calculate the amount of surface coverage of aminoferrocene molecules using Equation 4.2, 
which correlated to amount of carboxyl groups on the electrode surface.101 
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𝛤𝛤 = 𝑄𝑄/(𝑛𝑛𝑛𝑛𝑛𝑛)   (Equation 4.2) 
Here, Q is the oxidation peak area, n is the number of electron for aminoferrocene oxidation (n = 
1), F is Faraday’s constant, and A is the area of the working electrode (0.2 cm2).  
 The calculated amount of relative carboxyl terminals in bare graphite electrode and 
graphene-COOH coated graphite electrode were 6.72 ± 0.66 and 50.30 ± 8.94 pmoles cm-2 
respectively. The graphene coated electrode offered almost 8 times higher number of carboxyl 
terminals on the electrode surface. This ultimately enables the sensor surface to accommodate 
higher number of biological recognition elements, which in this case are insulin aptamers.  
4.3.3 Impedimetric characterization of the paper-based sensor 
 
 
 
 
 
 
 
Figure 4.6. Bode plot representing the stepwise assembly of the paper-based capacitive sensor. 
100 pM insulin spiked in 10% human serum was used for demonstrating the Bode plot after 
analyte capturing. EIS was obtained after each modification step by applying 10 mV AC 
waveform magnitude and scanning from 100,000 – 0.5 Hz. 
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 Figure 4.6 represents the Bode plot for stepwise assembly of molecules on the paper-
based electrode. The Bode plot represents the impedance and phase angle change for the stepwise 
electrode assembly after applying 10 mV AC potential and scanning in the frequency range of 
100,000 – 0.5 Hz. The immunosensing electrode behaves as a resistor at higher frequencies as 
impedance values remains constant given that resistance is independent of frequency. However, 
as we approach lower frequencies, the sensor starts to behave as a capacitor and the impedance 
starts to increase with decreasing frequencies. At lower frequencies (< 100 Hz), the 
immunosensor approaches an ideal capacitor as the phase angle approaches -90º indicating 
densely packed insulating layer.32 For monitoring capacitance change before and after the insulin 
capturing, we chose 10 Hz as the optimum frequency given that it relatively takes less time while 
still behaving as an ideal capacitor.  
4.3.4 Insulin dependent change in capacitance and amperometric signals 
 
 
 
 
 
 
 
Figure 4.7. Control subtracted capacitance response plot for different concentrations of insulin 
spiked in 10% serum and immobilized on graphene-COOH surface. The capacitance was 
monitored at 10 Hz frequency while applying a 10 mV AC potential. (N=3 replicates.) 
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Figure 4.7 represents the relative change in capacitance against different concentration of 
insulin spiked in 10% serum samples. The ΔC% represents the percentage change in capacitance 
before and after the immobilization of insulin molecules and is given by Equation 4.3, 
∆C% = 
(C1 - C0)
C0
 X 100%  (Equation 4.3) 
Here, C0 and C1 represents the capacitance before and after insulin immobilization respectively. 
This capacitive sensor exhibited a good dynamic range of 5 – 500 pM and a limit of 
detection (LOD) of 1.5 pM. These analytical values are clinically significant. Yagati et al. 
proposed a capacitive sensor for detecting insulin molecules where the capacitance decreased 
with increasing concentration of insulin as opposed to this study.22 This was attributed to increase 
in distance with increasing concentration of insulin due to formation of antigen-antibody 
complexes. However, other studies have mentioned increase in capacitance for increasing 
antigen-antibody complexes at lower frequencies.135 Especially in the case of aptamer-antigen 
complexes, capacitance has found to be increasing owing to increase in dielectric properties due 
to the formation of aptamer-antigen complexes.136- 138 
 
 
 
 
 
65 
 
Figure 4.8. (A) Amperometric response curves for different concentrations of insulin spiked in 
10% serum samples. (B) Control subtracted correlation of current with different concentrations of 
insulin spiked in serum. (N=3 replicates.) 
As mentioned prior, the paper-based immunosensor was further analyzed using 
amperometry. This was achieved by incubating the sensor surface with HRP-labeled anti-insulin 
polyclonal antibodies after the insulin incubation. The prepared electrodes were connected to a 
potentiostat and a 200 µL mixture of 0.1 mM HQ and 0.5 mM H2O2 was added to the surface 
while applying -0.1 V potential, and the current signals were monitored. Thus obtained current 
signals correlated to the concentration of insulin on sensor surface (Fig. 4.8-A). Figure 4.8-B 
represents the correspondence of control subtracted current signals to different serum insulin 
concentration. The analytical parameters of this amperometric immunosensor were comparable to 
the capacitive sensor. The exhibited dynamic range was 5 – 500 pM and an LOD of 1 pM.  
4.3.5 Validation of sensor with insulin ELISA  
To assess the clinical applicability of the both paper-based capacitive and amperometric sensors, 
we analyzed a type 2 diabetes patient serum sample (10% serum) using a commercial ELISA kit 
as well as with the paper-based immunosensor in both capacitive and amperometric platforms. 
The diluted patient sample was back calculated to determine the undiluted concentration of the 
patient sample. The patient sample analysis correlated well across all three immunosensing 
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techniques. The paper-based assay strategies required less time (capacitive ~ 2.5 h; amperometric 
~ 3 h) compared to ELISA technique where the assay time takes ~ 3 h excluding the time spent in 
manufacturing. 
 
 
 
 
 
 
 
 
Figure 4.9. Correlation of the paper-based capacitive and amperometric biosensors with 
commercial insulin ELISA kit for a type 2 diabetes patient sample. (N=3 replicates.)  
4.4 Conclusion 
The paper-based graphene electrode immunosensor measured serum insulin molecules in both 
enzyme-amperometric and label-free non-faradaic impedance techniques. Insulin aptamers were 
able to provide selectivity to capture insulin molecules in 10% serum samples. Amperometric and 
capacitance detection methods provided comparable results for measuring insulin molecules in 
clinically relevant levels. Capacitive detection of biomolecules can be performed in less number 
of steps and thus, less amount of time without the need for expensive enzymatic labels when 
compared to amperometric technique. However, manual electrode fabrication technique may not 
67 
 
be feasible for large scale production as well may present significant batch-to-batch variations. As 
a future outlook, we are focusing towards inkjet printing wax and electrodes to minimize above 
mentioned predicaments. Additionally, minimizing incubation time and sample volume and 
adapting the sensor system for measuring analytes in whole blood will be the emphasis of the 
future direction. Nonetheless, paper-based electrodes can be adopted as a cheaper alternative to 3-
electrode systems as well as screen printed electrodes when it comes to detecting biomolecules at 
point-of-care. 
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CHAPTER V 
 
 
CONCLUSION AND FUTURE OUTLOOK 
 
Since their inception, glucose biosensors (normal and diabetes related blood glucose 
concentration is present in several millimolar units) have seen immense success on diabetes 
management. Recently, insulin detection approaches in biofluids have gained significance for 
regulating glucose metabolism, and for potential applicability in identification of type 1 (insulin-
deficient condition) and type 2 (insulin-resistant condition) diabetic disorders, as well as for use 
in artificial pancreatic devices. In addition to insulin, other non-glucose molecules (e.g., 
autoantibodies, receptors, proteins, and other small molecules) are evolving as early predictive 
biomarkers of diabetes and diabetes related complications. The objective of this dissertation was 
to advance the current analytical capabilities for detecting insulin and diabetes autoantibodies by 
novel surface chemistry designs and provide quantitative insights. Simplicity of the sensor design, 
low-cost label-free paper designs, sensitivity, and clinically required detection limits are some of 
the unique advantages offered from the collective studies in this dissertation.  
In Chapter II, we reported that the combination of π-π stacking of pyrenecarboxylic acid 
(Py-COOH) over chemically carboxylated multiwall carbon nanotubes (MWNT-COOH) offers 
superior sensitivity compared to MWNT-COOH alone for serum insulin measurements. 
Additionally, quantitative details on the relative number of carboxyl groups and protein 
immobilization were presented for both MWNT-COOH/Py-COOH and MWNT-COOH surfaces. 
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The results indicated that enhancing the number of carboxylic acid groups on the carbon 
nanotubes surface enhanced the number of proteins immobilized, thus improving the dynamic 
range and limit of detection for serum insulin measurements. The approach discussed in the study 
is broadly applicable for biosensors, drug delivery, and catalytic systems.  
Chapter III demonstrated our initial exploration into the islet cell autoantibodies detection 
as type 1 diabetes predictive biomarker. The study presented surface-plasmon microarray 
detection of serum glutamic acid decarboxylase 65 autoantibody (GADA) utilizing the antigen 
GAD-65 as the biorecognition element. The binding events for the antigen-antibody complexes 
were studied on a carboxylated graphene and mercapto- monolayer surface for assessing 
analytical parameters among the two surfaces. Additionally, the binding parameters for the 
autoantibody-antigen complexes were also presented. Carboxylated-graphene modified 
immunoassembly on a gold surface-plasmon chip compared to self-assembled monolayer surface 
of mercaptopropionic acid (MPA) provided significantly larger binding affinity, higher 
sensitivity, and lower detection limits. Estimation of the relative surface carboxyl groups by 
covalent tagging of aminoferrocene showed that the graphene surface displayed a greater number 
of carboxyl groups than the MPA surface. X-ray-photoelectron-spectroscopy analysis showed 
more C−O and C=O functionalities on the graphene-COOH surface than on the MPA surface. 
The graphene-COOH coating on gold exhibited ~ 5.5-fold enhancement of plasmon signals 
compared with a similar coating on a plain glass surface. The binding-constant parameters can be 
useful as a quality-control checkpoint for reproducible and reliable production of large-scale 
biosensors for clinical bioassays. 
In Chapter IV, we demonstrated a paper-based platform for detecting serum insulin 
molecules as a cheap alternative to standard analytical laboratory techniques. The study reported 
non-faradaic impedance (label-free technique) for measuring serum insulin in picomolar range 
and provided analytical comparison of the paper-based biosensor with amperometric (labeled 
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technique) methods of insulin measurements. Both the techniques provided comparative dynamic 
range and lower limit of detection and were able to measure clinically relevant serum insulin 
concentrations. The study presented surface characterizations with quantitative estimation of 
carboxyl groups on the sensor surface. The study is reported as a low-cost option for detection of 
biomolecules. 
Overall, we demonstrated surface chemistry for detecting biomolecules of significance in 
diabetes management and prediction with clinical significance. Moving ahead, our objective to 
enhance the analytical parameters remains the same. Ultimately, we want to design and develop 
sensors for point-of-care testing capable of measuring analytes directly from undiluted biofluids. 
Multiplexed detection of biomarkers in a paper-based platform while still detailing on the surface 
characteristics and the sensors surface robustness and reproducibility is the scope of the future 
direction.  
71 
 
 
 
 
 
 
REFERENCES 
 
 
1. Hu, F. B.; Satija, A.; Manson, J. E. JAMA 2015, 313, 2319-2320. 
2. World Health Organization. Global report on diabetes. https://www.who.int/diabetes/global 
report/en/ (accessed June 17, 2019). 
3. Centers for Disease Control and Prevention. A Snapshot: Diabetes in the United States. 
https://www.cdc.gov/diabetes/library/socialmedia/infographics.html (accessed June 17, 
2019).  
4. American Diabetes Association. Diabetes Care 2017, 40, S11-S24. 
5. Stenström, G.; Gottsäter, A.; Bakhtadze, E.; Berger, B.; Sundkvist, G. Diabetes 2005, 54, S68-
S72. 
6. Quianzon, C. C.; Cheikh, I. J. Community Hosp. Intern. Med. Perspect. 2012, 2, 18701. 
7. Clark Jr, L. C.; Lyons, C. Ann. N. Y. Acad. Sci. 1962, 102, 29-45. 
8. Yoo, E.-H.; Lee, S.-Y. Sensors 2010, 10, 4558-4576. 
9. Chen, C.; Xie, Q.; Yang, D.; Xiao, H.; Fu, Y.; Tan, Y.; Yao, S. RSC Adv. 2013, 3, 4473-4491. 
10 Tonyushkina, K.; Nichols, J. H. J. Diabetes Sci. Technol. 2009, 3, 971-980. 
11. Weiss, M.; Steiner, D. F.; Philipson, L. H. Insulin Biosynthesis, Secretion, Structure, and 
Structure-Activity Relationships; MDText.com, Inc., South Dartmouth (MA), 2000. 
72 
 
 
12. American Diabetes Association. Diagnosing Diabetes and Learning about Prediabetes. 
http://www.diabetes.org/diabetes-basics/diagnosis/ (accessed June 30, 2019). 
13. Freckmann, G.; Hagenlocher, S.; Baumstark, A.; Jendrike, N.; Gillen, R. C.; Rössner, K.; 
Haug, C. J. Diabetes Sci. Technol. 2007, 1, 695-703. 
14. Muoio, D. M.; Newgard, C. B. Nat. Rev. Mol. Cell Biol. 2008, 9, 193-205. 
15. Weyer, C.; Hanson, R. L.; Tataranni, P. A.; Bogardus, C.; Pratley, R. E. Diabetes 2000, 49, 
2094-2101. 
16. Goetz, F. C.; French, L. R.; Thomas, W.; Gingerich, R. L.; Clements, J. P. Metabolism 1995, 
      44, 1371-1376. 
17. Singh, V.; Krishnan, S. Analyst 2014, 139, 724-728. 
18. Singh, V.; Krishnan, S. Anal. Chem. 2015, 87, 2648-2654. 
19. Singh, V.; Rodenbaugh, C.; Krishnan, S. ACS Sens. 2016, 1, 437-443. 
20. Singh, V.; Nerimetla, R.; Yang, M.; Krishnan, S. ACS Sens. 2017, 2, 909-915. 
21. Li, T.; Liu, Z.; Wang, L.; Guo, Y. RSC Adv. 2016, 6, 30732-30738. 
22. Yagati, A. K.; Park, J.; Cho, S. Sensors (Basel, Switzerland) 2016, 16, 109. 
23. Amouzadeh Tabrizi, M.; Shamsipur, M.; Saber, R.; Sarkar, S.; Besharati, M. Microchim. Acta 
2017, 185, 59. 
24. E. Bonifacio, Diabetes Care, 2015, 38, 989-996. 
73 
 
 
25. Ziegler, A. G.; Rewers, M.; Simell, O.; Simell, T.; Lempainen, J.; Steck, A.; Winkler, C.; 
Ilonen, J.; Veijola, R.; Knip, M.; Bonifacio, E.; Eisenbarth, G. S. JAMA 2013, 309, 2473-
2479. 
26. Falorni, A.; Örtqvist, E.; Persson, B.; Lernmark, Å. J. Immunol. Methods 1995, 186, 89-99. 
27. Walikonis, J. E.; Lennon, V. A. Mayo Clin. Proc. 1998, 73, 1161-1166. 
28. Zhang, B.; Kumar, R. B.; Dai, H.; Feldman, B. J. Nat. Med. 2014, 20, 948-953. 
29. Zhao, Z.; Miao, D.; Michels, A.; Steck, A.; Dong, F.; Rewers, M.; Yu, L. J. Immunol. 
Methods 2016, 430, 28-32. 
30. Amoroso, M.; Achenbach, P.; Powell, M.; Coles, R.; Chlebowska, M.; Carr, L.; Furmaniak, 
J.; Scholz, M.; Bonifacio, E.; Ziegler, A.-G.; Rees Smith, B. Clin. Chim. Acta 2016, 462, 60-
64. 
31. Katz, E.; Willner, I. Electroanalysis 2003, 15, 913-947. 
32. Sharma, R.; Deacon, S. E.; Nowak, D.; George, S. E.; Szymonik, M. P.; Tang, A. A. S.;   
Tomlinson, D. C.; Davies, A. G.; McPherson, M. J.; Wälti, C. Biosens. Bioelectron. 2016, 80, 
607-613. 
33. Li, M.; Cushing, S. K.; Wu, N. Analyst 2015, 140, 386-406. 
34. Mariani, S.; Minunni, M. Anal. Bioanal. Chem. 2014, 406, 2303-2323. 
35. Krishnan, S.; Armstrong, F. A. Chem. Sci. 2012, 3, 1015-1023. 
36. Yu, X.; Munge, B.; Patel, V.; Jensen, G.; Bhirde, A.; Gong, J. D.; Kim, S. N.; Gillespie, J.; 
Gutkind, J. S.; Papadimitrakopoulos, F.; Rusling, J. F. J. Am. Chem. Soc. 2006, 128, 11199-
11205. 
74 
 
 
37. Gong, K.; Du, F.; Xia, Z.; Durstock, M.; Dai, L. Science 2009, 323, 760-764. 
38. Reuillard, B.; Gentil, S.; Carriere, M.; Le Goff, A.; Cosnier, S. Chem. Sci. 2015, 6, 5139-
5143. 
39. Meredith, M. T.; Minson, M.; Hickey, D.; Artyushkova, K.; Glatzhofer, D. T.; Minteer, S. D. 
ACS Catal. 2011, 1, 1683-1690. 
40. Byers, J. C.; Güell, A. G.; Unwin, P. R. J. Am.  Chem. Soc. 2014, 136, 11252-11255. 
41. Zou, X.; Huang, X.; Goswami, A.; Silva, R.; Sathe, B. R.; Mikmeková, E.; Asefa, T. Angew. 
Chem. Int. Ed. 2014, 53, 4372-4376. 
42. Tran, P. D.; Le Goff, A.; Heidkamp, J.; Jousselme, B.; Guillet, N.; Palacin, S.; Dau, H.; 
Fontecave, M.; Artero, V. Angew. Chem. Int. Ed. 2011, 50, 1371-1374. 
43. Yan, Y.; Miao, J.; Yang, Z.; Xiao, F.-X.; Yang, H. B.; Liu, B.; Yang, Y. Chem. Soc. Rev. 
2015, 44, 3295-3346. 
44. Zhang, J.; Dai, L.; Xia, Z. Sci. Adv. 2015, 1, e1500564. 
45. Wang, Z.; Dai, Z. Nanoscale 2015, 7, 6420-6431. 
46. Tiwari, J. N.; Vij, V.; Kemp, K. C.; Kim, K. S. ACS Nano 2016, 10, 46-80. 
47. Lojou, E. Electrochim. Acta 2011, 56, 10385-10397. 
48. Wang, J. Electroanal. 2005, 17, 7-14. 
49. Wang, D.-Y.; Gong, M.; Chou, H.-L.; Pan, C.-J.; Chen, H.-A.; Wu, Y.; Lin, M.-C.; Guan, M.; 
Yang, J.; Chen, C.-W.; Wang, Y.-L.; Hwang, B.-J.; Chen, C.-C.; Dai, H. J. Am. Chem. Soc. 
2015, 137, 1587-1592. 
75 
 
 
50. Huang, S.; Liang, C.; Chen, Y.-J. Ind. Eng. Chem. Res. 2016, 55, 6060-6068. 
51. Li, H.; Chen, Q.; Han, B.-H. New J. Chem. 2016, 40, 3300-3307. 
52. Rabti, A.; Raouafi, N.; Merkoçi, A. Carbon 2016, 108, 481-514. 
53. Chen, R. J.; Zhang, Y.; Wang, D.; Dai, H. J.  Am. Chem. Soc. 2001, 123, 3838-3839. 
54. Walgama, C.; Means, N.; Materer, N. F.; Krishnan, S. Phys. Chem. Chem. Phys. 2015, 17, 
4025-4028. 
55. Krishnan, S.; Mani, V.; Wasalathanthri, D.; Kumar, C. V.; Rusling, J. F. Angew. Chem. Int. 
Ed. 2011, 50, 1175-1178. 
56. Singh, V.; Rodenbaugh, C.; Krishnan, S. ACS Sensors 2016, 1, 437-443. 
57. Zhang, Y.; Yuan, S.; Zhou, W.; Xu, J.; Li, Y. J. Nanosci. Nanotechnol. 2007, 7, 2366-2375. 
58. Prasad, K. S.; Walgama, C.; Krishnan, S. RSC Adv. 2015, 5, 11845-11849. 
59. Karachevtsev, V.A.; Stepanian, S. G.; Glamazda, A. Y.; Karachevtsev, M. V.; Eremenko, V. 
V.; Lytvyn, O. S.; Adamowicz, L. J. Phys. Chem. C 2011, 115, 21072-21082. 
60. Masheter, A. T.; Xiao, L.; Wildgoose, G. G.; Crossley, A.; Jones, J. H.; Compton, R. G. J. 
Mater. Chem. 2007, 17, 3515-3524. 
61. Armbruster, D. A.; Pry, T. Clin. Biochem. Rev. 2008, 29, S49-S52. 
62. Walgama, C.; Nerimetla, R.; Materer, N. F.; Schildkraut, D.; Elman, J. F.; Krishnan, S. Anal. 
Chem. 2015, 87, 4712-4718. 
63. Pihoker, C.; Gilliam, L. K.; Hampe, C. S.; Lernmark, Å. Diabetes 2005, 54, S52-S61. 
64. von Herrath, M.; Sanda, S.; Herold, K. Nat. Rev. Immunol. 2007, 7, 988-994. 
76 
 
 
65. Gan, M. J.; Albanese-O’Neill, A.; Haller, M. J. Current Problems in Pediatric and Adolescent 
Health Care 2012, 42, 269-291. 
66. Atkinson, M. A.; Eisenbarth, G. S. The Lancet 2001, 358, 221-229. 
67. Åkerblom, H. K.; Vaarala, O.; Hyöty, H.; Ilonen, J.; Knip, M. Am.  J.  Med. Genet. 2002, 115, 
18-29. 
68. Ziegler, A.-G.; Nepom, G. T. Immunity 2010, 32, 468-478. 
69. Bonifacio, E. Diabetes Care 2015, 38, 989-996. 
70. Verge, C. F.; Gianani, R.;  Kawasaki, E.;  Yu, L.;  Pietropaolo, M.;  Chase, H. P.;  Eisenbarth,  
G. S.; Jackson, R. A. Diabetes 1996, 45, 926. 
71. Heding, L. G. Diabetologia 1975, 11, 541-548. 
72. Andersen, L.; Dinesen, B.; Jorgensen, P. N.; Poulsen, F.; Roder, M. E. Clin. Chem. 1993, 39, 578-
582. 
73. Forest, J. C.; Masse, J.; Lane, A. Clin. Biochem. 1998, 31, 81-88. 
74. Miao, D.; Guyer, K. M.; Dong, F.; Jiang, L.; Steck, A. K.; Rewers, M.; Eisenbarth, G. S.; Yu, 
L. Diabetes 2013, 62, 4174-4178. 
75. Lee, J. W.; Sim, S. J.; Cho, S. M.; Lee, J. Biosens. Bioelectron. 2005, 20, 1422-1427. 
76. Choi, S. H.; Lee, J. W.; Sim, S. J. Biosens. Bioelectron. 2005, 21, 378-383. 
77. Cao, C.; Sim, S. J. Biosens. Bioelectron. 2007, 22, 1874-1880. 
78. Nguyen, H. H.; Park, J.; Kang, S.; Kim, M. Sensors 2015, 15, 10481-10510. 
79. Bonaccorso, F.; Sun, Z.; Hasan, T.; Ferrari, A. C. Nat. Photon. 2010, 4, 611-622. 
77 
 
 
80. Chiu, N.-F.; Huang, T.-Y.; Lai, H.-C.; Liu, K.-C. Nanoscale Res. Lett. 2014, 9, 445-451. 
81. Lee, H.; Choi, T. K.; Lee, Y. B.; Cho, H. R.; Ghaffari, R.; Wang, L.; Choi, H. J.; Chung, T. 
D.; Lu, N.; Hyeon, T.; Choi, S. H.; Kim, D.-H. Nat. Nano. 2016, 11, 566-572. 
82. Patil, A. V.; Fernandes, F. B.; Bueno, P. R.; Davis, J. J. Bioanalysis 2015, 7, 725-742. 
83. Yang, W.; Ratinac, K. R.; Ringer, S. P.; Thordarson, P.; Gooding, J. J.; Braet, F. Angew. 
Chem. Int. Ed. 2010, 49, 2114-2138. 
84. Ma, H.; Wu, D.; Cui, Z.; Li, Y.; Zhang, Y.; Du, B.; Wei, Q. Anal. Lett. 2013, 46, 1-17. 
85. Zeng, S.; Baillargeat, D.; Ho, H.-P.; Yong, K.-T. Chem. Soc. Rev. 2014, 43, 3426-3452. 
86. He, L.; Pagneux, Q.; Larroulet, I.; Serrano, A. Y.; Pesquera, A.; Zurutuza, A.; Mandler, D.; 
Boukherroub, R.; Szunerits, S. Biosens. Bioelectron. 2017, 89, 606-611. 
87. Zagorodko, O.; Spadavecchia, J.; Serrano, A. Y.; Larroulet, I.; Pesquera, A.; Zurutuza, A.; 
Boukherroub, R.; Szunerits, S. Anal. Chem. 2014, 86, 11211-11216. 
88. Geim, A. K. Science 2009, 324, 1530-1534. 
89. Zhu, Y.; Murali, S.; Cai, W.; Li, X.; Suk, J. W.; Potts, J. R.; Ruoff, R. S. Adv. Mater. 2010, 
22, 3906-3924. 
90. Schedin, F.; Lidorikis, E.; Lombardo, A.; Kravets, V. G.; Geim, A. K.; Grigorenko, A. N.; 
Novoselov, K. S.; Ferrari, A. C. ACS Nano 2010, 4, 5617-5626. 
91. Grigorenko, A. N.; Polini, M.; Novoselov, K. S. Nat. Photon. 2012, 6, 749-758. 
92. Wang, H.; Shi, L.; Yan, T.; Zhang, J.; Zhong, Q.; Zhang, D. J. Mater. Chem. A. 2014, 2, 
4739-4750. 
78 
 
 
93. Wu, H.; Zhao, W. F.; Hu, H. W.; Chen, G. H. J. Mater. Chem. 2011, 21, 8626-8632. 
94. Wu, N.; She, X.; Yang, D.; Wu, X.; Su, F.; Chen, Y. J. Mater. Chem. 2012, 22, 17254-17261. 
95. Ding, W.; Cai, J.; Yu, Z.; Wang, Q.; Xu, Z.; Wang, Z.; Gao, C. J. Mater. Chem. A. 2015, 3, 
20118-20126. 
96. Falahati‐Pour, S. K.; Lotfi, A. S.; Ahmadian, G.; Baghizadeh, A. J. Appl. Microbiol. 2015, 
118, 976-988. 
97. Song, X.; Wang, L.; Tang, C. Y.; Wang, Z.; Gao, C. Desalination 2015, 369, 1-9. 
98. Liao, T.; Yuan, F.; Yu, H.; Li, Z. Anal. Methods 2016, 8, 1577-1585.  
99. Stankovich, S.; Dikin, D. A.; Piner, R. D.; Kohlhaas, K. A.; Kleinhammes, A.; Jia, Y.; Wu, 
Y.; Nguyen, S. T.; Ruoff, R. S. Carbon 2007, 45, 1558-1565. 
100. Park, S.; An, J.; Piner, R. D.; Jung, I.; Yang, D.; Velamakanni, A.; Nguyen, S. T.; Ruoff, R. 
S.. Chem. Mater. 2008, 20, 6592-6594. 
101. Booth, M.A.; Kannappan, K.; Hosseini, A.; Partridge, A. Langmuir 2015, 31, 8033-8041. 
102. Santos. E. J; Kaxiras, E. Nano. Lett. 2013, 13, 898-902. 
103. Walgama, C.; Al Mubarak, Z. H.; Zhang, B.; Akinwale, M.; Pathiranage, A.; Deng, J.; 
Berlin, K. D.; Benbrook, D. M.; Krishnan, S. Anal. Chem. 2016, 88, 3130-3135. 
104. Nogues, C.; Leh, H.; Langendorf, C. G.; Law, R. H. P.; Buckle, A. M.; Buckle, M. PLoS 
ONE 2010, 5, e12152. 
105. Mani, V.; Wasalathanthri, D. P.; Joshi, A. A.; Kumar, C. V.; Rusling, J. F. Anal. Chem. 
2012, 84, 10485-10491. 
79 
 
 
106. Clinical Pharmacology & Therapeutics 2001, 69, 89-95. 
107. Svenningsson, P.; Westman, E.; Ballard, C.; Aarsland, D. Lancet Neurol. 2012, 11, 697-707. 
108. Molinuevo, J. L.; Blennow, K.; Dubois, B.; Engelborghs, S.; Lewczuk, P.; Perret-Liaudet, 
A.; Teunissen, C. E.; Parnetti, L. Alzheimers Dement. 2014, 10, 808-817. 
109. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; 
Li, Q. Cell Res. 2008, 18, 997-1006. 
110. Sattar, N. Diabetic Med. 2012, 29, 5-13. 
111. Füzéry, A. K.; Levin, J.; Chan, M. M.; Chan, D. W. Clinical proteomics 2013, 10, 13. 
112. Wu, L.; Qu, X. Chem. Soc. Rev. 2015, 44, 2963-2997. 
113. Topkaya, S. N.; Azimzadeh, M.; Ozsoz, M. Electroanalysis 2016, 28, 1402-1419. 
114. Hua, Q. Protein Cell 2010, 1, 537-551. 
115. Wang, Y.; Gao, D.; Zhang, P.; Gong, P.; Chen, C.; Gao, G.; Cai, L. Chem. Commun. 2014, 
50, 811-813. 
116. Sun, H.; Wu, S.; Zhou, X.; Zhao, M.; Wu, H.; Luo, R.; Ding, S. Microchim. Acta 2018, 186, 
6. 
117. Luo, X.; Xu, M.; Freeman, C.; James, T.; Davis, J. J. Anal. Chem. 2013, 85, 4129-4134. 
118. Rafiee, B.; Fakhari, A. R. Biosens. Bioelectron. 2013, 46, 130-135. 
119. Kosack, C. S.; Page, A.-L.; Klatser, P. R. Bull. World Health Organ. 2017, 95, 639-645. 
120. Berggren, C.; Bjarnason, B.; Johansson, G. Electroanalysis 2001, 13, 173-180. 
80 
 
 
121. Pumera, M. Chem. Soc. Rev. 2010, 39, 4146-4157. 
122. Ambrosi, A.; Chua, C. K.; Bonanni, A.; Pumera, M. Chem. Rev. 2014, 114, 7150-7188. 
123. Pumera, M.; Ambrosi, A.; Bonanni, A.; Chng, E. L. K.; Poh, H. L. TrAC Trends Anal. 
Chem. 2010, 29, 954-965. 
124. Guo, Z.; Hao, T.; Du, S.; Chen, B.; Wang, Z.; Li, X.; Wang, S. Biosens. Bioelectron. 2013, 
44, 101-107. 
125. Singh, M.; Holzinger, M.; Tabrizian, M.; Winters, S.; Berner, N. C.; Cosnier, S.; Duesberg, 
G. S. J. Am. Chem. Soc. 2015, 137, 2800-2803. 
126. Raccichini, R.; Varzi, A.; Passerini, S.; Scrosati, B. Nat. Mater. 2015, 14, 271-279. 
127. Premaratne, G.; Niroula, J.; Patel, M. K.; Zhong, W.; Suib, S. L.; Kalkan, A. K.; Krishnan, 
S. Anal. Chem. 2018, 90, 12456-12463. 
128. Ruscito, A.; DeRosa, M. C. Front. Chem. 2016, 4, 14. 
129. Jalalian, S. H.; Karimabadi, N.; Ramezani, M.; Abnous, K.; Taghdisi, S. M. Trends Food 
Sci. Technol. 2018, 73, 45-57. 
130. Pang, S.; He, L. Anal. Methods 2016, 8, 1602-1608. 
131. Patel, D. J. Curr. Opin. Chem. Biol. 1997, 1, 32-46. 
132. Patel, D. J.; Suri, A. K.; Jiang, F.; Jiang, L. C.; Fan, P.; Kumar, R. A.; Nonin, S. J. Mol. Biol. 
1997, 272, 645-664. 
133. Hermann, T.; Patel, D. J. Science 2000, 287, 820-825. 
81 
 
 
134. Niroula, J.; Premaratne, G.; Ali Shojaee, S.; Lucca, D. A.; Krishnan, S. Chem. Commun. 
2016, 52, 13039-13042. 
135. de Vasconcelos, E. A.; Peres, N. G.; Pereira, C. O.; da Silva, V. L.; da Silva, E. F.; Dutra, R. 
F. Biosens. Bioelectron. 2009, 25, 870-876. 
136. Qureshi, A.; Gurbuz, Y.; Kallempudi, S.; Niazi, J. H. Phys. Chem. Chem. Phys. 2010, 12, 
9176-9182. 
137. Qureshi, A.; Gurbuz, Y.; Niazi, J. H. Sens. Actuators B Chem. 2015, 220, 1145-1151. 
138.  Jo, N.; Kim, B.; Lee, S.-M.; Oh, J.; Park, I. H.; Jin Lim, K.; Shin, J.-S.; Yoo, K.-H. Biosens. 
Bioelectron. 2018, 102, 164-170. 
 
 
 
VITA 
 
Jinesh Niroula 
 
Candidate for the Degree of 
 
Doctor of Philosophy 
 
Dissertation:    QUANTITATIVE NANO-SURFACE CHEMISTRY FOR DIABETES 
SERUM BIOMARKER ASSAYS  
 
 
Major Field:  Chemistry 
 
Biographical: 
 
Education: 
 
Completed the requirements for the Doctor of Philosophy in Chemistry at 
Oklahoma State University, Stillwater, Oklahoma in July, 2019. 
 
Completed the requirements for the Bachelor of Science in Chemistry at 
Cameron University, Lawton, Oklahoma in 2012. 
 
Experience:   
 
Graduate Teaching and Research Assistant, Oklahoma State University  
(2014 - 2019). 
Research: Electrochemical and Surface Plasmon Biosensors/Arrays 
 
Laboratory Technician, SOS Employment Group, Well Services Division, 
West-Texas, Schlumberger Tech-Corp., USA (2013). 
 
Tutor / Head Tutor, Upward Bound and Open Doors, and Department of 
Mathematics, Cameron University (2008-2012). 
 
Professional Memberships:   
 
Oklahoma Chapter of the Electrochemical Society (2017) 
Phi Lambda Upsilon, Honorary Chemical Society (2017) 
